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The classical paradigm of breast cancer (BC) management has been 
challenged by recent advances in the understanding of molecular biology, which 
is increasingly encouraging attempts to move away from protocol-based in favor 
of a personalized approach. This project aimed to test circulating tumor DNA 
(ctDNA) and circulating tumor cells (CTCs) to characterize the disease, and 
monitor patients with BC including both non-invasive and invasive cases. 
For this purpose, 41 patients with newly diagnosed ductal carcinoma in situ 
(DCIS), and 61 triple negative BC (TNBC) patients treated with neoadjuvant 
chemotherapy were analyzed. Primary tumor mutations identified by targeted- 
gene sequencing were validated, and tracked in 182 plasma samples 
longitudinally collected at multiple time-points by droplet-digital Polymerase 
Chain Reaction. In recurrent TNBC patients, plasma DNA underwent direct 
targeted-gene assay, and CTCs were analyzed for Copy Number Alterations 
(CNAs). 
In DCIS patients, ctDNA from baseline samples was evaluable in 71% of cases, 
with Variant Allele Frequency (VAF) values ranging between 0.001% and 5%, 
independently of clinico-pathological features, and likewise at initial diagnosis 
and at relapse. In TNBC patients, the number of primary tumor mutations 
showed a downward trend after treatment; proficient genes involved in the 
immune pathways were associated to response; and surgical samples of non 
responsive cases presented alterations in druggable pathways. ctDNA after 
treatment was associated with increased risk of relapse, and its prognostic 
value remained worthy even after adjusting for age, residual disease, systemic 






ctDNA was undetectable in non-recurrent cases. Conversely, ctDNA was 
detected in 83% of recurrent cases, and antedated the clinical diagnosis up to 
13 months. Notably, recurrent cases without ctDNA developed loco-regional, 
contralateral, and bone-only disease. At clinical progression, CTCs presented 
chromosome 10 and 21q CNAs whose network analysis showed connected 
modules including HER/PI3K/Ras/JAK signaling, and immune response. 
These findings extend the value of liquid biopsy to further clinical scenarios by 
reporting - unlike previous studies - the presence of ctDNA in noninvasive BC; 
and substantiate the development of ctDNA in invasive BC as an exploitable 
tool, either alone or with CTCs, for personalized TNBC management. 
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Introduction 2  
1.1 Breast cancer 
 
Epidemiology - Breast cancer is a significant public health problem, accounting 
for approximately 24% of new cancer cases diagnosed in women each year 
worldwide [Bray F et al., 2018]. According to the International Agency for 
Research on Cancer, nearly 2 million new cases were diagnosed in 2018, and 
incident cases are expected to increase by almost 50% in the next two decades, 




Figure 1. Breast cancer a) Stages of disease progression, modified from 
https://www.caperay.com; b) Types and relative incidence; c) Treatment algorithm. 
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The risk of developing breast cancer increases with age, with a probability of 
developing breast cancer of 2.3% up to the age of 49 (1 in 43 women), 5.4% in the 
50-69 age group (1 in 18 women) and 4.5% in the 70-84 age group (1 in 22 
women) [AIRTUM - AIOM, 2020].  
This correlation with age could be linked to the endocrine proliferative stimulus that 
the mammary epithelium undergoes over the years and to the possible 
accumulation of genetic and epigenetic alterations that can cause an imbalance 
between oncogenes and suppressor genes. The incidence curve rises 
exponentially until the menopause years (around 50-55 years), then slows down 
with a plateau after the menopause, and then rises again after 60 years. 
This specific trend is related both to the endocrinological history of the woman and 
to the presence of screening programs. 
Thanks to mammography screening, breast cancer primary tumors are now 
routinely found at the sub-clinical level [Siegel RL et al., 2018] (Figure 1, a). With 
the discovery of breast cancer at earlier stages there is the risk that some indolent 
or slowly growing lesions, i.e., ductal carcinoma in situ will be overdiagnosed or 
overtreated [Siu AL et al., 2016; Morrow M et al., 2015]. Reasonable estimates 
show the overdiagnosis rate with mammography screening to be 1-10% [reviewed 
by Pashayan N et al., 2020]. Until we are able to discriminate with certainty 
between cases of breast cancer that will not cause damage or relapse and those 
that will, this small overdiagnosis is bound to persist. It should not, however, be 
used as a reason to delay screening or to widen the screening interval, because 
neither strategy will decrease the small amount of overdiagnosis that exists. 
Improvements in personalized treatment will hopefully diminish the morbidity of 
treatment and, therefore, the significance of overdiagnosis. Though most women 
present with localized potentially curable tumors, incurable and lethal relapses 
remain frequent in clinical practice. Indeed it is estimated that 7% of all cancer 
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deaths are attributed to breast cancer, making it the second leading cause of 
cancer-related deaths, and the first among females [Siegel RL et al., 2018]. 
Histological classification - Most breast malignancies arise from epithelial 
elements and are categorized as carcinomas (Figure 1, b). Breast carcinomas are 
a diverse group of lesions that differ in microscopic appearance and biologic 
behavior, although these disorders are often discussed as a single disease. The in 
situ carcinomas of the breast are either ductal (also known as intraductal 
carcinoma) or lobular. This distinction is primarily based upon the growth pattern 
and cytologic features of the lesions, rather than their anatomic location within the 
mammary ductal-lobular system. The invasive breast carcinomas consist of 
several histologic subtypes; the estimated percentages are reported in Figure 1, b. 
Other subtypes, including metaplastic breast cancer and invasive micropapillary 
breast cancer, all account for less than five percent of cases [Dillon DA et al., 
2009]. 
Molecular classification - Breast cancer is a heterogeneous disease and patients 
with tumors apparently similar in clinicopathological features may present a 
different clinical course (Figure 2). Following investigations of gene expression 
analysis by microarray methods that identified an intrinsic gene list of 496 genes 
[Sorlie T et al., 2001; Sorlie T et al., 2003], four subtypes of invasive carcinomas 
were identified [Van de Vijver MJ et al., 2002]: 
- "Luminal A": neoplasms with marked expression of hormone receptors; 
 
- "Luminal B": neoplasms that, although expressing hormone receptors, have a 
high risk of recurrence, due to the high proliferative index correlated with high 
expression of proliferation genes; 
- "HER2": characterized by the presence of HER2 expression; 
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- "Basal like": tumors characterized by the absence of expression of hormone 
receptors and HER2 and increased expression of basal cytokeratins (e.g. CK5/6 
and CK14). 
These subgroups have also proved to be prognostically important, Luminal A 
carcinomas having a favourable prognosis, much better than Luminal B, and 
HER2 positive and Basal-like carcinomas having the worst prognosis of all 
subgroups. 
Within these subtypes there is a high heterogeneity. In the light of new 
pathological and molecular knowledge there is a definition of further subtypes of 
breast cancer. For example, another subgroup of breast cancers has been 
identified with no expression of hormone receptors and HER2, but with stem cell 
markers, low expression of claudin (cell-cell junction proteins) and accompanying 
lymphocytic infiltrate, termed "claudin low" and characterised by poor prognosis 
[Prat A et al., 2010] . In addition, a gene expression analysis of 587 triple negative 
breast cancers identified six different subtypes with different molecular biology and 
clinical behaviour: Basal like 1 and 2 (BL1 and BL2), immunomodulatory (IM), 
mesenchymal (M), mesenchymal stem-like (MSL) and Luminal Androgen 
Receptor (LAR) [Lehmann BD et al., 2011]. In clinical practice, 
immunohistochemical evaluation of hormone receptor status, Ki67 and HER2, 
allows surrogate identification of the four phenotypic subgroups of breast cancer 
that present a relative correspondence with the four derived from gene expression 
profiles [Cheang MC et al., 2009]. 
Immunophenotypic groups of clinical relevance and with important therapeutic 
implications, including systemic therapy, are: 
- Luminal A: hormone receptor positive, HER2 negative and low proliferative 
activity (which frequently includes some special histotypes such as tubular 
carcinoma, lobular carcinoma classic type). Luminal A breast cancer cases are 
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represented by tumors with positive estrogen receptors, with positive progesterone 
receptors (i.e., ≥ 20%), with negative HER2, and Ki67<20%. 
- Luminal B: hormone receptor positive, HER2 negative and high proliferative 
activity; 
- HER2 positive luminals: hormone receptor positive, HER2 overexpressed 
(immunohistochemistry reaction score 3+) or amplified, any proliferative activity 
value; 
- HER2 positive (non-luminal): HER2 overexpressed (3+ score of 
immunohistochemistry reactions) or amplified (FISH or other methods) and both 
hormone receptors negative 
- Triple-negative: absence of hormone receptor expression and HER2 negativity. 
The correspondence between the immunohistochemically detected triple negative 
phenotype and the intrinsic Basal Like subgroup detected on a gene basis only 
exists in about 80% of cases, further demonstrating the extreme heterogeneity 
present within these subgroups. The triple negative subgroup includes some 
special histological types such as typical medullary and adenoid cystic, which have 
a low risk of recurrence. Retrospective analyses have associated the four 
subtypes with differences in disease-free survival, sites of recurrence and overall 
survival (Figure 2) [Kennecke H et al., 2010]. 
 
Figure 2. Breast cancer classification according to histological findings and molecular subtypes, 
adpated from http://www.pathophys.org. 
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1.1.1 Current management 
 
Systemic treatment was initially employed along with surgery and radiotherapy for 
extensive loco-regional disease control, but became a main component of breast 
cancer management once breast cancer was recognized as a systemic disease at 
onset due to the potential for lymphatic and blood dissemination [Veronesi U et al., 
1981]. 
Traditionally, systemic therapy has been administered to breast cancer patients 
after surgery (adjuvant therapy). Recently, however, neoadjuvant systemic therapy 
has been regarded as an equally effective option when compared to adjuvant 
therapy [Early Breast Cancer Trialists' Collaborative Group, 2018]. Whereas 
neoadjuvant anti-hormonal therapy is mainly recommended for postmenopausal 
patients with hormone receptor positive breast cancer [Yeo B and Dowsett M, 
2015], neoadjuvant chemotherapy is increasingly utilized for all breast cancer 
subtypes (Figure 1, c). 
The use of systemic treatment in the neoadjuvant setting is associated with 
equivalent overall survival rates compared to the use of the same systemic 
treatment in the post-operative setting. Specifically, a single-patient meta-analysis 
compared the outcomes of neoadjuvant as compared to adjuvant systemic therapy, 
based on data from 4,756 women enrolled in ten studies initiated between 1983 
and 2002 [Early Breast Cancer Trialists' Collaborative Group, 2018]. No significant 
difference was observed in terms of distant recurrence rates (15-year risk: 38.2% 
vs 38%, Relative Risk [RR] 1.02, CI 95% 0.92-1.14, p=0.66), breast cancer-related 
mortality (15-year risk: 34. 4% vs 33.7%, RR 1.06, CI 95% 0.95-1.18, p=0.31) or 
 
overall mortality (15-year risk: 40.9% vs 41.2%, RR 1.04, CI 95% 0.94-1.15, 
p=0.45), between neoadjuvant and adjuvant chemotherapy. Systemic neoadjuvant 
treatment was found to be associated with an increased risk of local recurrence 
(local recurrence at 15 years: 21.4% vs. 15.9%, HR 1.37, CI 95% 1.17-1.61, 
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p=0.001), attributable at least in part to the increased use of conservative surgery, 
with the increased risk essentially confined to women in trials where surgery had 
been omitted. 
Thus, in the face of comparable distant recurrence rates and overall survival 
between systemic treatment administered in the adjuvant as compared to 
neoadjuvant setting, the advantages of neoadjuvant systemic treatment are listed 
below: 
- Primary tumor down-staging to allow conservative surgical treatment in patients 
who would otherwise be candidates for demolitive (i.e., mastectomy) surgery; 
- Treatment of locally advanced breast cancer (stage IIB-IIIC), since, irrespective 
of the subtype, conservative surgery is not amenable in the majority of cases; 
- Treatment of early-stage breast cancer (including stages I-IIA) when 
conservative surgery is not feasible (e.g. because of a high tumour-to-mammary 
ratio or when the expected cosmetic outcome is suboptimal because of a 
particular tumour location). 
- Possibility of allowing prognostic assessment based on pathological response 
after neoadjuvant systemic treatment. The positive prognostic role - at individual 
patient level - of achieving complete pathological response after neoadjuvant 
systemic treatment is well established. In particular, in a large meta-analysis 
sponsored by FDA (CtNeoBC), which included 11,955 patients enrolled in 12 
clinical trials, a highly significant association - at individual patient level - was 
reported between achievement of pathological complete response (defined as 
absence of residual invasive disease in the breast and lymph nodes - ypT0/is, N0) 
and survival, in terms of event-free survival (EFS) and overall survival (OS) 
[Cortazar P et al., 2014]. This association has been reported in the overall 
population and in all breast cancer subtypes. However, the strength of this 
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association was found to be more robust in subtypes characterized by greater 
biological aggressiveness, such as HER2 positive and triple negative. 
 
 




- Possibility of calibrating post-operative treatment on the basis of the presence of 
residual disease after neoadjuvant systemic treatment. Indeed, the presence of 
residual disease after neoadjuvant systemic treatment is a recognized negative 
prognostic factor. In this context, depending on the subtype of breast cancer, 
several treatment options are now available for patients who have not achieved 
pathological complete response after standard neoadjuvant systemic treatment 
(therefore considered "high risk"), including “rescue” adjuvant chemotheray and/or 
treatment including targeted therapy, immunotherapy and conjugated antibodies. 
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Hence, neoadjuvant chemotherapy increases the rate of breast conserving 
surgery [Kaufmann M et al., 2012], and allows monitoring of treatment and tumor 
biological response, providing unique opportunities for development of both 
individualized treatment strategies and drug development [Bardia A and Baselga J, 
2013] (Figure 3). 
1.1.2 Future perspectives 
 
During the last decades, enormous advances have been made in the study and 
dissection of tumor molecular characteristics, thanks to the advent of the -omics 
era. These advances have led to the origin of precision oncology as a branch of 
precision medicine [Meric-Bernstam F and Mills GB, 2012], shifting from a “one 
size fits all” therapeutic approach towards the identification of “the right treatment, 
for the right patient, at the right time”. The applications of tumor molecular profiling 
encompass all the stages of cancer management [Cronin M and Ross JS, 2011] 
including screening, prognosis, patient stratification for predicting response to 
therapy, and for the selection of personalized therapies, monitoring of treatment 
effectiveness, and follow-up for early detection of relapse and metastasis 
occurrence [http://precision.fda.gov]. 
The heterogeneity of breast cancer can be addressed by mutational profile, and 
recent studies have demonstrated that individual cases are composed of a mosaic 
of different clones with different sets of genetic aberrations [Gagan J and Van 
Allen EM, 2015; Zarvadas D et al., 2015]. Massively parallel sequencing analyses 
revealed that primary breast cancers have a complex repertoire of somatic genetic 
alterations, which vary according to hormone receptor status [Cancer Genome 
Atlas Network, 2012; Nik-Zainal S et al., 2016]. 
Recurrent     mutated     genes are few,     namely     TP53,     PIK3CA,  GATA3, 
MAP3K1 and CDH1. Notably, among the subset of rarely mutated genes,   
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 druggable genetic alterations have been reported, affecting HER2 [Bose R et al., 
2013], ESR1 [Toy W et al., 2013], and AKT1 [Bleeker FE et al., 2008]. More 
recently, studies have demonstrated that a large subset of breast cancer present 
intra-tumor genetic heterogeneity, whose level and type differ between estrogen 





Figure 4. Primary tumor somatic mutations in breast cancer. Bars depict proportions of ER 
positive and ER negative samples harbouring mutations in mutation-driver genes. Red and blue 
points indicate for each gene, the proportions of recurrent and inactivating mutations, respectively. 
Asterisks indicate genes highlighted in: COSMIC, Cancer gene census from the Catalogue of 
Somatic Mutations in Cancer; TCGA-BRCA, TCGA breast cancer study; TCGA-PAN, TCGA pan- 
cancer analysis. Estrogen Receptor (ER) status available for 2,410 tumors. MAPK, mitogen- 
activated protein kinase. The genes are grouped by pathway or function. Modified from Pereira B et 
al., 2016. 
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Given this genetic heterogeneity, it is conceivable that in the transition from 
primary to metastatic disease, the metastatic process itself as well as the 
therapeutic interventions administered in the adjuvant setting may result in clonal 
selection. In this context, the evaluation of primary versus metastatic breast 
cancer would lead to the identification of genes whose genetic alterations are 
specific or enriched in metastatic lesions compared to the respective primary 
tumors. Hence, therapeutic strategies targeted at predominant aberrations could 
be ineffective, especially in the case of recurrent disease were temporal evolution 
is likely to occur [Nik-Zainal S et al., 2012; Stephens PJ et al, 2012; Siu LL, 2013]. 
Academic enterprises are therefore encouraged to build a longitudinal map of 
breast cancer evolution that interrogates both primary and recurrent disease sites. 
To achieve this, traditionally, multiple biopsies would be necessary. Instead of 
repeated biopsies, a more convenient strategy could be blood-born biomarkers, 
such as circulating tumor DNA (ctDNA) and circulating tumor cells [Alix- 
Panabieres C, Pantel K., 2013; Dawson SJ et al., 2013; Speicher MR, Pantel K, 
2014]. 
1.2 Circulating tumor DNA 
 
DNA circulates freely in the blood of both healthy and sick individuals [Mandel P 
and Metais P, 1948]. A crucial discovery was made when Leon and colleagues 
demonstrated that the levels of cell-free DNA (cfDNA) were higher in patients than 
in healthy subjects [Leon SA et al., 1977]. This was followed by the work 
conducted by Stroun and colleagues which traced the neoplastic origin of cfDNA 
present in the plasma of cancer patients [Stroun M et al., 1989]. The mechanism 
by which the tumor-derived fraction of cfDNA, commonly named circulating tumor 
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report that 1 ml plasma from a patient with cancer contains approximately 1,500 
diploid genome equivalents (GE) (~10 ng DNA) (Figure 5, a), with considerably 
blood draw yields on average 4 ml plasma containing 6,000 GE (12 × 103 
~0.01% (that is, the ability to detect 1 somatic variant in 12,000 copies). If the VAF 
of ctDNA corresponds to 0.1%, there are on average just six molecules per tube 
carrying the respective mutation, which may be affected by stochastic sampling 
DNA (ctDNA), is released in circulation is not entirely known. Apoptosis and 
necrosis of cancer cells are thought to be the major contributors. Other 
possibilities include active secretion of DNA by tumor cells, as well as potential if 
not minor contributions from circulating tumor cells [reviewed by Kustanovich A et 
al. 2019]. 
ctDNA has received enormous attention during the last decade owing to its huge 
potential as a minimal invasive tumor biomarker to aid in the diagnosis, treatment, 
and prognosis of tumor diseases, showing greater sensitivity compared to the 
previously used blood biomarkers [reviewed by Bronkhorst AJ et al., 2019]. 
However, the detection of ctDNA at an early stage has shown greater challenge 













(Figure 5, b) as reported by Heitzer E et al. 2019.  
Furthermore, when one circulating primary tumor mutation is admixed with 20,000 
or more normal copies, such as in the case of patients with primary tumors ≤1 
cm, the use of 4 ml of plasma will likely not contain a single cancer genome for 
sequencing, thus rendering the diagnosis of cancer impossible due to sampling 
error [Lievens A et al. 2016]. Consequently, the reliability, accuracy, and 
Although the amount of cfDNA in patients with cancer varies widely, most studies 
molecules per region or gene), which implies a theoretical sensitivity limit o 
higher amounts often observed in patients with metastatic cancer. A typical 10 m 
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Figure 5. Cell-free DNA input and somatic variants detection 
 
A) The graph shows the relationship between the amount of input DNA (in nanograms) and the 
number of template molecules in terms of diploid genome equivalents (GE). B) The graph shows 
the relationship between the number of input molecules (copies) and the probability that 10 
mutated copies will be detected in a total of 1,500, 6,000 or 10,000 copies at different variant allele 
frequencies (VAFs). For a reliable detection of a mutation with a VAF of 0.1% (10 mutated copies), 
at least 10,000 template molecules (5,000 GE or 33ng of input DNA) are necessary. Modified from 
Heitzer E et al. 2019. 
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1.2.1 Technological approaches to ctDNA analysis 
 
Current methods to identify sequence alterations in cfDNA can be divided in 
polymerase chain reaction (PCR)- and Next-Generation Sequencing (NGS)-based 








PCR-based techniques are used for single locus assays, and were historically the 
first to be implemented to identify mutant KRAS in pancreatic carcinoma 
[Sorenson GD et al., 1994]. Although useful, allele specific PCR has very limited 
analytical sensitivity [Wan JCM et al., 2017], and it is currently being substituted by 
more sensitive approaches, such as droplet digital PCR (ddPCR) [Heitzer E et al., 
2019]. While in traditional PCR a single sample offers only a single measurement, 
in ddPCR the sample is partitioned into 20,000 nl-sized droplets. This partitioning 
enables the measurement of thousands of independent amplification events within 
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a single sample. ddPCR-based approaches have high sensitivity (ranging between 
0.001% and 0.01%), allow ctDNA absolute quantification, and are currently being 
used to detect specific known mutations, such as the main driver mutations of the 
primary tumor, or variants associated with response to drugs in individual tumor 
types. 
NGS-based techniques have been developed to interrogate multiple mutations in 
parallel and to identify de novo mutations, and range from the analysis of several 
tens of mutations, to a genome-wide analysis of cfDNA by whole-exome 
sequencing, or whole-genome sequencing [Newman AM et al., 2014; Zehir A et al., 
2017; Gray ES et al., 2019]. 
In general, the larger the analysis, the more expensive and difficult is to obtain 
high sensitivity for mutation calling. Targeted sequencing (also known as NGS 
panels) involves the sequencing of specific loci after selective amplification by 
PCR (amplicon-based) or hybrid capture-based enrichment [Forshew T et al. 2012; 
Gale D et al., 2018; Chicard M et al., 2018]. NGS panels, usually designed to 
include cancer specific genes of interest with a diagnostic or prognostic value, are 
being widely used to assess tumor heterogeneity, to follow clonal evolution under 
and after treatment, and to identify potential resistance mutations. Non-targeted 
approaches are instead reserved to research in the field of immuno-therapy, 
where mutation load (i.e., the number of non synonymous mutations found in a 
tumor) has emerged as a putative biomarker of the response to treatment. 
1.3 Circulating tumor cells 
 
Circulating tumor cells (CTCs) were discovered by Thomas Ashworth in the 1860s 
during an autopsy of a patient with metastatic cancer. These cells have the ability 
to detach from a primary or metastatic tumor site, penetrate the vessel wall and 
enter the circulatory system [Zhang et al., 2017; Domínguez-Vigil et al., 2018]. 
Introduction 17  
CTCs can be isolated as single cells or clusters from the blood of patients with 
cancer. 
1.3.1 Detection and enumeration 
 
The differences between CTCs and normal blood cells in physical and biological 
properties had led to the development and commercialization of several CTC 
detection platforms, which can be categorized as label-dependent or -independent 
(Habli Z et al., 2020). 
 
 
Figure 7. Label-dependent and -independent CTCs detection. Commercialized technologies for 
CTC detection, enumeration and count. CTCs can be detected based on their molecular or 
physical properties. Examples of commercial boxes. Adapted from Habli et al., 2020. 
 
 
Among the leading label-dependent platforms, the FDA-approved Cell Search® 
system (Menarini Silicon Biosystems) captures CTCs using antibodies directed 
against EpCAM, and defines CTCs as nucleated CK8-positive, CK18-positive or 
CK19-positive, and CD45-negative cells. Important correlations between CTC 
count and prognosis have already been reported using Cell Search® in patients 
with different type of cancer, including breast cancer [Cristofanilli M et al., 2004; 
Cristofanilli M et al., 2005; Riethdorf S et al., 2007]. Specifically, in the metastatic 
setting, patients with ≥5 CTCs per 7.5 ml blood showed reduced progression-free 
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survival, and those with <5 CTCs per 7.5 ml improved overall survival [Pantel K et 
al., 2008; Bidard FC et al., 2014]. Furthermore, an increasing baseline CTC count 
was associated with a progressively worse prognosis in a recent metanalysis of 
clinical trials with neoadjuvant therapy for patients with early-stage breast cancer 
[Bidard FC et al., 2018]. However, Cell Search® CTC enumeration has some 
limitations. First, EpCAM expression in tumor cells decreases during the epithelial- 
to-mesenchymal transition that accompanies tumor progression [Rao CG et al., 
2005]; and different studies showed that CTCs may not show EpCAM expression 
on their surface [Sieuwerts AM et al., 2009]. Therefore, an exquisitely EpCAM- 
based technology is able to detect just a limited number of CTCs. Secondly, cell 
isolation through the Cell Search® system is followed by cell fixation, which 
prevents further viable CTC characterization. Finally, sensitivity of Cell Search® 
system is 1 cell per ml, and detected CTCs are usually contaminated, the purity of 
captured cells ranging between 60–70% [Habli Z et al., 2020]. Label-independent 
approaches allow the isolation of CTCs with a low epithelial phenotype because 
these platforms discriminate CTCs from other cells based on physical 
characteristics such as size, density, deformability, and electrical properties 
(Figure 7). 
The Parsortix® system (Angle plc, Guildford, UK) is an example of such an 
approach because of its scale architecture, which gradually decreases in width to 
4.5 µm, favors the embedding of CTCs, which are larger than other circulating 
cells while preserving their morphology [Obermayr E et al., 2015]. This microfluidic 
system is used as an initial enrichment step for the subsequent application of 
dielectrophoresis-based techniques (DEP) capable of separating CTCs, and 
leukocytes based on differences in their conductivities through the use of a non- 
uniform alternating electric field [De Luca F et al., 2016]. The advantage of the 
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DEP strategy is that it allows enumeration and also isolation of single CTCs for 
downstream molecular analyses. 
1.3.2 Molecular characterization 
 
To achieve accurate genomic analysis of CTCs at the single-cell level, whole 
genome amplification (WGA) of DNA from a single cell must be performed with 




Figure 8. Genomic DNA (gDNA) amplification from single cells 
 
 
Currently WGA methods include PCR, and multiple displacement amplification 
(MDA) [Blainey PC, 2013]. PCR-based approaches typically conduct PCR 
amplification using degenerate oligos as primers (i.e., DOP-PCR [PicoPlex]), or 
linker adaptors with universal sequences ligated to the DNA fragments (i.e., LM- 
PCR [GenomePlex and Ampli1]). On the other hand, the isothermal MDA-based 
methods (i.e., Repli-g) use high-fidelity Phi29 DNA polymerase for amplification of 
larger DNA fragments across the genome with a 1000 fold higher fidelity than 
PCR-based approaches. WGA methods that hybridize the principles of PCR and 
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MDA-based approaches have also been reported (i.e., multiple annealing and 
loop-based amplification cycling [MALBAB]). The optimal WGA method per se 
does not exist as all these approaches present technical issues (Table 1). 
Common amplification errors include preferential amplification with secondary 
allelic imbalance (AI), PCR reaction failure in an allele, (i.e., allele drop out [ADO]), 
and false positive detection of SNVs. 
 
Table 1. Strength and weakness of WGA systems 
 
Thanks to random primers, which bind the DNA at multiple points to ensure 
extensive coverage, PCR-based approaches are able to amplify about 96% of the 
genome at least 1000 times. However, PCR-based methods can produce artifacts 
and generate DNA fragments less than 1 kb in length, which are unusable for 
many subsequent applications. In contrast, MDA methods ensure intact products 
of significant length (>10 kb) and a reduction in amplification errors up to four 
orders of magnitude. However, the caveat of MDA is that it generates non-uniform 
coverage and can therefore result in important distortions of copy-number states. 
In general, PCR-based methods are thought to generate increased uniformity, but 
cause more errors at the single nucleotide level than MDA-based methods. MDA- 
based methods suffer from ADO and AI drawbacks, which may prevent 
applications in CNA analysis. Hybrid approaches finally have broader genomic 
coverage while maintaining sufficient uniformity for CNA analysis, can still result 
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in >30% base dropout, a potentially significant sacrifice in the sensitivity to detect 
single nucleotide mutations. In addition to considering the characteristics of the 
individual methods, there is also the need to use the one with fewer steps and 
reduced reaction volume to minimize or completely avoid possible contamination 
of the DNA sample by the surrounding environment. After WGA the amplified DNA 
is used to construct libraries for NGS. While high-coverage WGS is the most 
comprehensive and data-rich approach, alternative methods can deliver genetic 
information for a lower cost. Low-pass WGS (typically defined as <1X coverage of 
the genome) is twenty-fold less expensive than complete genome sequencing, yet 
provides data for useful comparative genomic analyses especially for structural 
variation such as CNAs. 
1.3.3 Copy Number Alteration (CNA) analysis 
 
Studies exploring the landscape of CNAs have considerably advanced our 
knowledge of breast cancer biology, with translational efforts leading to advances 
in the clinic. This was the case for the amplification of the ERBB2 (HER2) 
oncogene, which defines a biological subtype of breast cancer, and whose 
targeting led to the development of therapeutic agents that increased the survival 
of HER2 amplified breast cancer patients [Baselga J and Albanell, 2001; Arteaga 
and Engelman, 2014]. Additionally, numerous studies have demonstrated the 
utility of copy number information in the prognostic stratification of breast cancer 
patients [Russnes HG et al., 2010; Shah SP et al., 2012], and studies of the genes 
targeted by this class of somatic mutations have paved the way for new 
therapeutic targets [GatzaML et al., 2014; Cai Y and Sablina AA, 2016]. 
However few studies have explored the role of CNAs in the CTCs of breast cancer 
patients [Riebensahm C et al., 2019; Kanwar N et al., 2015]. Specifically, CNA 
patterns showed a high clonality among different CTCs of the same patient, and 
aberrations thought to be unique to CTCs were detected at subclonal frequencies 
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within primary tumors, indicating pre-existing genetic signatures for metastasis. 
These subclonal alterations were enriched in CTCs and metastases, pointing 
towards the selection of a more “fit” component of tumor cells with survival 
advantages. Lastly, these CTCs may also be the chemo-resistant portion that 
escapes systemic treatment, or acquire resistance during disease progression, as 
unique genomic alterations may impinge on pathways of tumor progression, such 
as NOTCH, or treatment resistance, such as PI3K [Kim C et al., 2018; Li et al., 
2020; Litviakov NV et al., 2020]. Although these studies have limitations, 
represented by the low number of cases analysed, and the different disease 
settings investigated, their data suggest that CTCs are a useful tool for the study 
of intratumoural heterogeneity to identify rare aberrations within primary tumors 
that make them more able to spread; moreover, they may be useful in monitoring 
the development of treatment-resistant subclones as breast cancer progresses. 
1.4 Scope of the thesis 
 
To gain a perspective on the scope of the problem, we should consider that each 
year approximately 2 million new cases of breast cancer will be diagnosed 
worldwide, and about one-fourth of those patients will experience recurrence [Bray 
F et al., 2018]. The classic paradigm of breast cancer management, i.e., decision 
making based on clinical and pathological parameters, has not significantly 
changed over decades [Curigliano G et al., 2017], and most clinical decisions are 
guided by balancing treatment benefits (reduced risk of local recurrence and 
increased survival), and drawbacks (toxicity and costs). Randomized clinical trials 
have shown that adjuvant treatment of resected invasive and non invasive, i.e., 
ductal carcinoma in situ (DCIS), breast cancer are able to reduce the risk of 
relapse as compared to observation. However, up to half of patients receiving 
these therapies would in fact not have failed, and thus had been unnecessarily 
treated. Therefore, it is necessary to develop predictive and prognostic biomarkers 
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to minimize overtreatment, and to promptly identify patients at risk of relapse for 
case strategies [Appierto V et al., 2017]. 
HYPOTHESIS 
 
Liquid biopsy may identify women with non invasive breast cancer, provide an 
early readout of the effect of systemic therapy, help to explore breast cancer 
heterogeneity, and guide treatment of recurrent disease. 
SPECIFIC AIMS 
 
 To assess ctDNA in newly diagnosed and recurrent cases of DCIS;
 
 To use ctDNA as a marker of response to neoadjuvant chemotherapy;
 
 To unravel differences in tissue and ctDNA baseline/post-treatment pairs;
 




ctDNA in women at high risk of invasive breast cancer 
 






Figure 9. Evolution of DCIS from a normal duct to invasive cancer - Schematic cross sections 
of the duct (top row), and corresponding microscopic images (bottom row), modified from Casasent 
et al., 2017. 
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Free surgical margins and postoperative radiotherapy are the most important and 
significant prognostic factors for local disease control, but cannot reliably predict 
the risk of invasive recurrence after DCIS [reviewed by Salvatorelli L et al., 2020]. 
It has been reported that DCIS displays genomic heterogeneity similarly to that 
found in IBC. Likewise, the majority of synchronous DCIS and IBC exhibit similar 
genomic profiles [Shee K et al., 2019]. Nevertheless, recent analysis of mutational 
profiling of DCIS and matched adjacent IBC revealed intratumor genetic 
heterogeneity, and clonal selection [Martelotto LG et al., 2017]. 
Based on these considerations, we seek to evaluate ctDNA mutations in DCIS and 
matched primary tumor specimens in women who underwent treatment with 
curative intent and developed or not loco-regional relapse, with the final aim of 
paving the way for using ctDNA as a tool to stratify DCIS patients according to 
their risk of recurrence. 
ctDNA to identify patients less likely to respond to systemic therapy 
Neoadjuvant therapy is increasingly being used to treat breast patients with the 
expectation that treatment can reduce the size or extent of cancer before surgery, 
thus making the surgical procedures easier, and more likely to be curative. 
Numerous studies have demonstrated that the burden of pathologically detected 
residual disease after neoadjuvant therapy is associated with long term prognosis, 
as the absence of invasive cancer in surgical specimens – i.e., pathological 
complete response (pCR) – defines patients with favorable outcome [Cortazar P et 
al., 2014]. Unfortunately, only a minority of patients treated with neoadjuvant 
therapy achieve a pCR. The underlying reasons remain a major challenge. 
This project aims to analyze the mutational profile of primary tumor, residual 
disease, and matched plasma samples to develop minimally invasive biomarkers 
to anticipate tumor response, to address the determinants of poor response at the 
molecular level, and to seek alternative strategies for unresponsive patients. 
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Figure 10. Clinical application of liquid biopsy in the neoadjuvant setting. 
Adapted from https://www.genengnews.com 
 
 
ctDNA to fully capture tumor heterogeneity 
 
High-depth sequencing of plasma DNA can be used to interrogate the mutational 
profile of recurrent disease before overt relapse and, in cancer cases with 
intratumor heterogeneity, assess whether ctDNA reflected that of the original 
primary breast cancer or rather the subsequent recurrence. Therefore, this work 
aims at using direct ctDNA sequencing to evaluate tumor heterogeneity in 
recurrent BC cases. 
CTCs to inform on the mechanisms of tumor progression 
 
Finally we aimed to assess if the characterization of single CTCs could provide 
information on tumor molecular features and on response/resistance to treatment 
in patients with breast cancer. Therefore, CTCs were collected, enriched and 
analyzed in recurrent cases after neoadjuvant therapy, and single CTC molecular 
characterization was used to study the evolution of breast cancer disease in 
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2.1 Patient information and biological samples collection 
 
The work of this dissertation was conducted on different patient populations, 
namely patients diagnosed with ductal carcinoma in situ that subsequently 
relapsed or not (DCIS study); and patients with invasive triple negative breast 
cancer treated with preoperative chemotherapy, surgery with curative intent, and 
followed up over time (Neoadjuvant study). 
 
 
Figure 11. Schematic representation of DCIS and neoadjuvant study design 
 
 
DCIS study - This was a retrospective study on newly diagnosed DCIS patients 
referred to Fondazione IRCCS Istituto Nazionale dei Tumori - Milano between 
January 2012 and June 2018, and treated with breast conserving surgery or 
mastectomy fulfilling the following criteria: availability of a formalin-fixed paraffin- 
embedded (FFPE) sample from the surgical specimen of the primary DCIS and 
matched invasive breast cancer in recurrent cases; no distinct invasive neoplastic 
components other than DCIS by revision of two dedicated pathologists; minimal 
tumor cellularity of 50%; negative margins (no tumor on ink); availability of plasma 
samples (minimum volume required 2.5 ml) at initial diagnosis and at recurrence; 
PBMC as a source of germline DNA. Patients with a previous or synchronous 
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contralateral breast cancer (DCIS or invasive) were excluded, as were patients 
with DCIS associated with lobular carcinoma in situ. Cases with and without 
recurrence were matched according to known prognostic variables, i.e., age at 
diagnosis, tumor size and grade, hormone receptor and HER2 expression, type of 
surgery, and adjuvant treatment, i.e., endocrine and/or radiotherapy. 
Neoadjuvant study - This was composed of two portions: the first was a 
retrospective analysis of mutational profile of pre- and post treatment primary 
tumor samples; the second was a prospective study to test the clinical value of 
ctDNA and CTCs in the context of clinical practice. Patients included were all 
treated at Fondazione IRCCS Istituto Nazionale dei Tumori - Milano, for invasive 
breast cancer, fulfilling the following criteria: ER and PR negative status as defined 
by immunohistochemical staining of fewer than 1% of tumor cell nuclei; HER2 
negative status as defined by IHC score 0-1 or IHC: 2+ with a negative 
chromogenic in situ hybridization (CISH) result; anthracycline/taxane-based 
neoadjuvant chemotherapy and breast and axillary surgery; availability of a FFPE 
sample from initial tumor biopsy and/or surgical specimen; minimal tumor 
cellularity of 50%; availability of plasma samples (minimum volume required 2.5 ml) 
at different time points, prior, during, after neoadjuvant therapy, and/or follow-up 
(minimum two drawings); PBMC as a source of germline DNA. Treatment efficacy 
was assessed by pCR as defined by the absence of invasive breast cancer in the 
breast and axillary nodes, and event free survival (EFS). EFS events were defined 
as post-surgery breast cancer relapse, second primary malignancy, or death for 
any cause. EFS time was measured from the date of NAC starting to the date of 
event, whichever occurred first; time was censored at the date of last follow-up for 
patients alive and without events. Stromal Tumor-Infiltrating Lymphocytes (sTILs) 
were assessed on a single hematoxylin-eosin stained slide, and scored according 
to pre-defined criteria  [Salgado R et al., 2015]. All cases were independently 
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evaluated by two experienced breast cancer pathologists blinded to treatment data 
and follow-up. Breast surgery was performed after a maximum of six weeks from 
the conclusion of neoadjuvant chemotherapy. 
Collection, use, and analysis of specimens in DCIS and neoadjuvant studies were 
approved by the institutional review board, and all patients signed an informed 
consent form to allow the research on tumor samples after the completion of 
diagnostic procedures, and on blood drawing. Due to the explorative nature of the 
study, no statistical hypothesis was postulated. 
2.2 DNA extraction from FFPE tissues and buffy coat 
 
Tumor DNA was isolated from four sections of primary tumor FFPE tissues (10 µm 
thick slides with tumor cellularity ≥50%) using the GeneRead DNA FFPE Kit 
(Qiagen, Valencia, CA) according to manufacturer’s instruction. Buffy coat DNA 
(for germ line DNA) was extracted using the QIAamp DNA Mini Kit (Qiagen) 
according to manufacturer’s instruction. The quality and the quantity of isolated 
DNA were assayed using the Agilent BioAnalyzer DNA High Sensitivity kit (Agilent 
Technologies, Santa Clara, CA) and the Qubit dsDNA HS kit (Life Technologies), 
respectively. 
2.3 Tissue targeted Next Generation Sequencing 
 
Sequencing of hotspot regions of 50 genes contained in the Ion AmpliSeq 
Cancer Hotspot Panel v2 (Thermo Fisher), i.e., HS panel, was performed by 
employing Ion S5 XL System (Thermo Fisher). 
Patients with enough DNA samples were also analyzed by sequencing of 409 all- 
exon genes contained in the Ion AmpliSeq Comprehensive Cancer Panel, i.e., 
CCP, with germ line DNA extracted from PBMC belonging to the same patients 
using the same Thermo Fisher platform. 
Ten ng or 40 ng of genomic DNA were used to amplify 50 gene hotspot regions 
using the Ion AmpliSeq Library Kit2.0 (Thermo Fisher) or the 409 all-exon genes 
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contained in the Comprehensive Cancer Panel (Thermo Fisher) according to the 
manufacturer’s manual (MAN0006735 rev 5.0). Amplicons were ligated to P1 and 
Barcode adapters using DNA Ligase. Barcoded libraries were purified using 
AMPure Beads XP (Beckman Coulter, Pasadena, CA), and PCR-amplified for a 
total of five cycles. After a second round of purification with AMPure Beads, the 
amplified libraries were sized, their quality was assessed using the Agilent 
BioAnalyzer DNA High Sensitivity kit (Agilent Technologies, Santa Clara, CA), and 
DNA was quantified using the Qubit dsDNA HS kit (Thermo Fisher). In particular, 
due to the FFPE origin of the DNA, dsDNA fragments with a length range of 50- 
150 bp were selected for both panels. Emulsion PCR and sample enrichment were 
performed using the Ion One touch 2 instrument according to the manufacturer’s 
instruction. Briefly, an input concentration of DNA library obtained with the first 
amplification step was added to the emulsion PCR master mix, and the Ion sphere 
particles (ISPs) and a double phase (oil/water) PCR was performed. Template 
preparation was performed using the Ion Chef instrument according to the 
manufacturer’s instruction. 530 and 540 chips were used to sequence samples on 
Ion S5 XL next-generation sequencing system using Ion S5 XL sequencing kits 
and following the manufacturer’s instructions. 
2.3.1 Sequencing data analysis 
 
Sequencing data were mapped to the human reference genome (hg19) using the 
TMAP algorithm implemented in the Torrent Suite software version 4.4.3 with 
default parameters. Tissue samples processed with Ion AmpliSeq  Cancer 
Hotspot Panel v2 and Ion AmpliSeq Comprehensive Cancer Panel were 
analyzed with AmpliSeq CHPv2 single sample workflow and AmpliSeq CCP w1.1 
– Tumor-Normal pair workflow of Ion Reporter version 5.10, respectively. To 
reduce the number of false positive calls, and obtain a list of confident somatic 
mutations we discarded variants passing at least one of the following filters: (i) 
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phred quality score< 30; (ii) strand bias p-value< 0.01; (iii) number of variant- 
supporting reads< 7; (iv) variant allelic frequency (VAF)< 5% and depth< 500 X; 
(v) allele frequency≥ 1% in the 1000 Genomes Project European population, or 
ExAC non-Finnish European population; (vi) variant allelic frequency (VAF) in 
normal sample≥ 10% (only for CCP); (vii) depth in normal sample< 10X. The 
confirmation of tumor somatic mutations was assessed using ad hoc ddPCR 
assays. When ddPCR assays wet-validated by the manufacturer were not 
available, custom mutation-specific ddPCR assays were designed using the 
Thermo Fisher Scientific custom SNP genotyping assay tool or Bio-Rad Mutation 
Detection Assay online design tool. The specific assays are detailed in the table 
below. 
Table 2 Mutation-specific ddPCR assays designed for each case 
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 GTAGATGGCCATGG  
 CAGCTGCACAGGGCAGGTCTTGGCCAG  
























































 ATGGTGGTACAGTCA  











 GACGC  
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 TGGGGACCCTGGG  









 TGCACAGGGCAGGTCTT  
















 AAACAACACCCTGGT  








 AGTTCCAAGGCCTCA  









 CGCGGACGCGGGT  









In the table are listed the mutation selected for each patient and the sequences used to 
design ddPCR assays on the online tools according to manufacturer instructions. 




2.4 DNA extraction from plasma samples 
 
Blood was separated into plasma aliquots within 2 hour from blood drawn by 
centrifugation at 4°C and stored at −80°C until assayed; no thawing accident 
occurred during storage. A second full speed centrifugation was performed after 
plasma thawing before cfDNA extraction using the QIAamp Circuling Nucleic Acid 
Kit (Qiagen) according to manufacturer’s instruction. DNA was eluted in 70  l of 
sterile distilled water. 
2.5 ddPCR analysis of tissue and plasma DNA 
 
The confirmation of tumor somatic mutations in tissue and the presence of ctDNA 
in plasma were assessed using ad hoc ddPCR assays. One single mutation was 
selected per patient. When multiple mutations were identified in a single tumor 
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sample, the mutation with the highest allelic fraction or the one with an already 
manufactured assay available in our laboratory was selected. Custom mutation- 
specific ddPCR assays were designed using the Thermo Fisher custom SNP 
genotyping assay tool or alternatively Bio-Rad Mutation Detection Assay online 
design tool. 
ddPCR was performed on the QX200 ddPCR™ system (Bio-Rad) in a total 
reaction volume of 21 µl including 1x ddPCR supermix for probes without dUTP 
(Bio-Rad), 9 µM each primer, 5 µM probe, and 7 µl of pre-amplified plasma DNA. 
Reactions were partitioned into a median of ~14,000 droplets per well in a QX200 
droplet generator according to the manufacturer’s instructions. Droplets from each 
sample were transferred into a 96-well PCR plate for amplification on a C1000 
Touch™ Thermal Cycler (Bio-Rad), incubating the plates at 95°C for 10 min 
followed by 40 cycles of 94°C for 30 s and 55°C for 60 s, then 10 min incubation at 
98°C. Plates were read on a Bio-Rad QX200 droplet reader (Bio-Rad) using 
QuantaSoft program (Bio-Rad). All the experiments were performed in triplicate 
including in every run three negative controls: i) no DNA template (NTC); ii) wild 
type (wt) genome (Promega); iii) cfDNA extracted from a pool of healthy donors. A 
sample was considered positive only when three or more FAM-positive droplets 
were detected in each replicate. Samples displaying only double-positive droplets 
containing both wt and mutant DNA templates were considered as false positives. 
Variant allele fraction (VAF) was calculated as follows: VAF (%) = [mutant copies / 
(wild-type + mutant copies)] x 100. 
2.6 Pre-amplification of plasma DNA 
 
Prior to ddPCR analysis, plasma DNA was pre-enriched by amplification using 
TaqMan® PreAmp Master Mix Kit (Thermo Fisher). Sample elution volume was 
reduced by Eppendorf Concentrator 5301 (Epperdorf) to 14 µl. Pre-amplification 
reaction was performed in a volume of 10 µl containing 4 µl of DNA template, 5 µl 
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of pre-amplification mastermix, and 1 µl of the same specific primers and probes 
designed for dPCR (at a final dilution of 0.05x). The amplification reaction was 
initiated by incubation of samples at 95°C for 10 minutes followed by 12 cycles of 
95°C for 15 seconds, 60°C for 4 minutes. The pre-amplified PCR products were 
then diluted 1:100-1:500 and 7 µl of dilutions were used to perform ddPCR. 
2.7 Plasma direct sequencing 
 
Circulating-free DNA (cfDNA) sequencing was performed using Oncomine 
Pan‐Cancer Cell‐Free Assay (Thermo Fisher) to identify genomic alterations 
among 272 amplicons from 52 cancer-related genes. The assay minimizes false 
positives by removing randomly incorporated errors through unique molecular tags 
attached to the gene-specific primers. Libraries were prepared following 
manufacturer’s instructions. 
Library purifications were carried out with AMPure XP magnetic beads (Beckman 
Coulter, Inc., Brea, CA, USA), and library quantification was performed using the 
Ion Library TaqMan Quantitation kit. For sequencing, libraries were diluted to a 
final concentration of 100 pM and after pooling, the concentration was adjusted to 
50 pM. Template preparation and chip loading were carried out on Ion Chef 
System (Thermo Fisher, Palo Alto, CA, USA). Eight samples were loaded on Ion 
550 chips and sequenced in an Ion Torrent S5XL Sequencer (Thermo Fisher, Palo 
Alto, CA, USA). 
2.7.1 Sequencing data analysis 
 
Raw sequencing data were analyzed using Torrent Suite Software (v5.12). 
Sequencing coverage was analyzed using the Coverage Analysis (v.5.10.0.3) plug-
in. Raw reads were aligned to the human reference genome hg19. 
Plasma samples processed with Oncomine™ Pan-Cancer Cell-Free Assay were 
analyzed with Oncomine TagSeq Pan-Cancer Liquid Biopsy w2.2 Single Sample 
workflow of Ion Reporter version 5.12 with default setting of germline low- 
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stringency parameters (minimal variant frequency of 0.1%, minimum variant 
quality of 10, maximum strand bias of 0.98, and minimum variant score of 10). 
2.8 Circulating Tumor Cells 
 
2.8.1 Enrichment and identification 
 
Blood samples (10 ml) collected in K2EDTA tubes were subjected to CTC 
enrichment with Parsortix® (Angle plc, Guildford, UK) within 1 h from blood draw. 
Enriched cells were harvested according to manufacturer’s instructions and fixed 
for 20 min at room temperature (RT) with 2% paraformaldehyde. Fixed samples 
were stained immediately or within 24 h from enrichments. Mean Parsortix’s 
recovery rates (previously investigated using 5 different cell lines spiked in healthy 
donor blood at final concentrations ranging between 25–50 cells/10 mL) were 81% 
(range 75–90%, depending on the cell line). 
Fixed samples were fluorescently stained with phycoerythrin (PE)-labeled 
antibodies against epithelial markers EpCAM (clone HEA-125, Miltenyi Biotec, 
Bergisch Gladbach, Germany, working dilution 1:11 for 10 min at 4o C), 
cytokeratins (pan cytokeratin clone C11, Abcam, San Francisco, CA, USA, and 
pan cytokeratin clone AE1/AE3, NSJ Bioreagents, San Diego, CA, USA, working 
dilution 1:10 for 10 min at RT), and EGFR (clone 423103, SantaCruz 
Biotechnology, Dallas, TX, USA, working dilution 1:11 for 10 min at 4o C), and with 
allophycocyanin (APC)-labeled antibodies recognizing leukocytes and monocytes: 
CD45 (clone 5B1, Miltenyi Biotec, working dilution 1:11 for 10 min at 4o C), 
CD14 (clone M5E2, BD Biosciences Pharmigen, San Diego, CA, USA, working 
dilution 1:20 for 10 min at 4o C), and CD16 (clone 3G8, BD Biosciences Pharmigen, 
working dilution 1:20 for 10 min at 4o C). Nuclei were stained with 1 g/mL Hoechst 
33342 (Sigma-Aldrich, Saint Louis, MI, USA) for 5 min at RT. The labeling 
procedure did not lead to significant loss of cells. Labeled cells were analyzed 
using the DEPArray™ (Menarini Silicon Biosystems, Bologna, Italy) within 2 days 
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from staining to visualize and recover single cells manually selected based on 
fluorescence labeling and morphology. 
Selected single epithelial or double-negative (PE-ve/APC-ve) cells were recovered 
for downstream molecular analyses. CTC enrichments by Parsortix® lasted about 
3 h, fixation lasted 20 min, and the cell selection and recovery process with the 
DEAPrray lasted about 3–4 h depending on the number of cells recovered from 
the patient 4.5. 
2.8.2 Molecular characterization 
 
Recovered single cells and pools of white blood cells (WBC) were subjected to 
whole genome amplification employing the Ampli1 WGA kit (Menarini Silicon 
Biosystems). Amplified DNA quality was checked with the Ampli1— QC kit (Silicon 
Biosystems), and a low-pass whole genome sequencing (lpWGS) to detect copy 
number aberrations was performed using the Ampli1-Low Pass kit (Menarini 
Silicon Biosystems) for barcoded libraries preparation, followed by sequencing 
with the IonTorrent Ion S5-system (Thermo Fisher, Waltham, MA, USA), using the 
Ion530 chip according to manufacturer’s instructions. 
2.8.3 Sequencing data analysis 
 
WGS sequences were aligned to the human reference genome (hg19) using tmap 
aligner tool on Torrent_Suite 5.4.0. CNAs were predicted by using QDNAseq 11.0 
with the following settings: minMapq=37, window=500kb. “Gain” and “loss” calls 
were filtered out by residual (> 4 SD) and black list regions reported in ENCODE 
database [Scheinin et al., 2014]. Segmented copy number data of each sample 
were extracted starting from logRatio value and used for downstream analysis 
performed by R software [https://www.R-project.org/.]. Functional enrichment 
analysis of gene lists extracted from most altered regions between CTCs for using 
Gene Ontology (GO) biological process terms and KEGG pathways was 
performed using the ClusterProfiler Bioconductor package [Yu G et al., 2012]. 
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Enrichment with p-value< 0.05 was considered for KEGG pathways or GO terms, 
respectively. 
2.9 Development of a protocol for ctDNA and CTC analysis 
 
The standard paradigm for ctDNA analysis involves the identification of somatic 
genomic alterations in tumor tissue, the design of PCR-based assays to detect 
and confirm these alterations, and the application of these assays to quantify 
accurately ctDNA in plasma (Figure 12). 
 
 




As mentioned, the main challenge for the use of liquid biopsy is the detection of a 
minor allelic fraction of mutant DNA on fragmented cfDNA. This requires the 
implementation of standardized operating procedures to ensure reliable results. To 
this end, the following steps were fine-tuned for cfDNA extraction, and ctDNA 
analysis. 
2.9.1 Optimization of pre-analytical aspects 
 
1. Source - ctDNA was obtained from plasma rather than from serum, according 
to the joint American Society of Clinical Oncology (ASCO), and College of 
American Pathologists (CAP) [Merker JD et al., 2018]. Indeed, leukocyte-derived 
normal DNA, which could dilute the ctDNA fraction, is lower in plasma fraction. 
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2. Tubes - Blood samples were collected in EDTA, and processed within a 
maximum of two hours from blood drawing to avoid the risk of leukocyte lysis, 
which could dilute the ctDNA fraction. 
3. Plasma extraction - A first centrifugation at 1700 × g for 10 min was performed 
to remove cells. After supernatant harvesting, plasma was collected and 
centrifuged again at 14,000 × g   (high-speed centrifugation) for 10 min to remove 
all cellular-derived contaminants. 
4. Storage - Plasma was aliquoted into single-use fractions and stored at -80 ◦C. 
 
5. Isolation - Studies directly comparing different ctDNA extraction methods are 
lacking. However, a recent experience has found comparable ctDNA yields when 
using either magnetic beads or silica-based membranes [Carpi FM et al., 2011]. 
The spin-column based method - currently used at our labs - takes advantage of 
the fact that DNA binds to silica. The sample containing DNA is added to a column 
containing a silica membrane and chaotropic salts. The chaotropic salts disrupt the 
hydrogen bonding between strands and facilitate binding of the DNA to silica by 
causing the nucleic acids to become hydrophobic. This exposes the phosphate 
residues so they are available for adsorption. The DNA binds to the silica, while 
the rest of the solution is washed out using ethanol to remove chaotropic salts and 
other unnecessary constituents (Figure 13). The DNA can then be re-hydrated 
with aqueous low salt solutions allowing for elution of the DNA from the beads. 





6. Quantification - Nucleic acid quantification was performed in a cuvette 
spectrophotometer, where the monochromator optical system provided light at 260 
nm, the absorbance peak for DNA. In addition, nucleic acid samples were also 
measured at 280 nm, which is the absorbance peak for protein. The ratio of the 60 
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nm and 280 nm measurements provided a determination of the purity of the 





Figure 13. Spin-column based method for DNA extraction 
 
 
2.9.2 Optimization of analytical aspects 
 
In theory, all the molecular techniques allowing to detect a mutation can be used. 
However, dealing with minimal fraction of ctDNA requires highly sensitive 
techniques. ddPCR approach allows absolute quantification with a sensitivity as 
high as 0.001%. ddPCR consists of the emulsification of extracted ctDNA, master 
mix, and Taqman reagents in droplets in order to isolate a single DNA molecule in 
each droplet. Two colors can be distinguished, the target mutant codon of interest 
and the conserved sequence, defining negative or positive droplets, respectively. 
As ddPCR system is prone to variability in the number of compartments that are 
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generated and/or accepted into the analysis, this essentially corresponds to a form 
of sub-sampling which may in turn add variation to the quantification. 
This is especially true for reactions with targets at very low abundance. It has been 
reported that a minimum compartmentalisation of 30% (7,000 droplets) is required 
to quantify down to 1%, and this percentage reaches 50% up to 12,000 to quantify 
down to 0.5%. In addition, limited yields of cfDNA may also decrease the 
specificity of mutation detection as a very small amount of PCR-generated errors 
can cause considerable noise, even in samples from healthy individuals [Lievens 
A et al., 2016; Ono Y et al., 2017]. 
To circumvent the limitations posed by the limited volume of plasma available and 
maximize ctDNA detection, we decided to perform a targeted enrichment step of 





Figure 14. Output of pre-amplification to overcome sub-sampling Blue circle: ctDNA identified 
in pre-amplified samples. 
 
 
Specifically, pre-amplification (12 cycles) of the regions of interest was performed 
by conventional PCR with the same mutation detection assays used for the 
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subsequent ddPCR analysis. The pre-amplified samples were diluted five fold in 
PCR grade water prior to further manipulation.The following controls were set up 
for each pre-amplification reaction: (i) a wild type genome sample as a negative 
control, to verify the specificity of the assay; (ii) a sample without template DNA to 
test for contamination; and (iii) the DNA sample extracted from the tumor to check 
that the mutation frequency was not altered by pre-amplification (Figure 15). Pre- 
amplified products were stored at -20°C, and analysed by ddPCR. 
 
Figure 15. VAFs estimated by NGS, ddPCR with or without pre-amplification. Somatic primary 
tumor mutations tested in ddPCR with (Y axis) or without (X axis) pre-amplification showed a high 





2.9.3 Workflow of targeted sequencing of plasma cell-free DNA 
 
Genomic profiling of plasma samples by direct targeted NGS was performed by 
Oncomine Pan-Cancer Cell-Free Assay, covering DNA target regions containing 
hotspots variants of 52 relevant genes in pathogenetic, and resistance molecular 
mechanisms in breast cancer. 
1. Enrichment process - This NGS assay applied unique molecular identifiers 
(UMIs) to improve the sensitivity by decreasing the amount of sequencing artifacts. 
With the recommended input of 20 ng cfDNA, the use of UMIs enabled a limit of 
detection (LoD) as low as 0.1%. 
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2. Library preparation - Library quantities were determined by qPCR and then 
diluted to a final concentration of 50 pM. Next, sample barcoded libraries were 
pooled together for template preparation, loaded onto a chip and sequenced on a 
Ion Torrent S5XL Sequencer (ThermoFisher Scientifific). 
3. Annotation - Analysis of variants were locally carried out using preconfigured 
parameter settings for liquid biopsy application. Raw sequencing data were 
analyzed using Torrent Suite Software (v5.12). Sequencing coverage was 
analyzed using the Coverage Analysis (v.5.10.0.3) plug-in. The manufacturer 
recommends a Median Read Coverage (MedReadCov) >25,000, and Median 
Molecular Coverage (MedMolCov) >2500 to detect a variant with a VAF of 0.1%. 
Raw reads were aligned to the human reference genome hg19. Plasma samples 
were analyzed with Oncomine TagSeq Pan-Cancer Liquid Biopsy w2.2 Single 
Sample workflow of Ion Reporter version 5.12 with default setting of germline low- 
stringency parameters. 
4. Reproducibility - ddPCR was tested on cfDNA samples to report concordance. 
 
2.9.4 CTC analysis in house pipeline 
 
This study aimed at assessing the role of molecular characterization of single CTC 
as a strategy to selectively distinguish clones responsible for treatment resistance/ 
metastatic progression. To such a purpose, the recently published protocol 
developed in our lab [Reduzzi C et al., 2017] (Figure 16) was applied according to 
the following steps: 
1. Enrichment by the Parsortix® Cell Separation System which is an epitope 
independent process, and consequently agnostic to cellular genotype or 
(immuno)phenotype. 
2. Labeling with antibody cocktails against epithelial and leukocyte markers. 
 
3. Visualization through DEPArray™ (Menarini Silicon Biosystems, Bologna, 
Italy). 
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4. Recovery of epithelial and double-negative cells. 
 
5. Downstream molecular analyses. 
 
CTC enrichment by Parsortix® lasted about 3 hours, fixation lasted 20 min, and the 
cell selection and recovery process with the DEPArray™ lasted about 3-4 hours 
depending on the number of collected cells. 
 
Figure 16. The workflow of Circulating Tumor Cell analysis 
 
 
At the end of the DEPArray™ processing, single CTCs were collected in 0.2 ml 
PCR-tubes in a drop (around 20 µl) of SB115 buffer. Before starting the WGA it 
was necessary to perform a volume reduction procedure to leave the cell in 1 µl of 
PBS. After volume reduction, cells were lysed to allow WGA, which was followed 
by a quality assessment check through a PCR-based approach. This way, we 
assigned a genome integrity index (GII) to each amplified DNA. The GII value 
could range from 0 to 4: 0 indicated a failure in the WGA, probably due to the loss 
of the cell during volume reduction; 1-2 corresponded to a low-quality sample; 3-4 
was indicative of high-quality amplified DNA. After quality check, DNA was 
sequenced by low pass WGS to confirm or exclude the malignant nature of each 
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3.1 DCIS study 
 
3.1.1 Patient cohort 
 
The search for DCIS cases with available tumor tissue and perioperative blood 
samples stored at the Institutional bio-bank between October 2012 and July 2018 
retrieved a total of 160 cases. Among these, 10 (6.25%) secondary events 
occurred, i.e., 7 invasive ipsilateral breast tumor recurrences, and 3 contralateral 
breast cancer. This figure is consistent with literature data, considering both the 
median follow-up of this case series, and a yearly rate≤ 1% of breast cancer 
recurrence [EBCTCG, 2010]. 
We initially matched 1:2 the 7 cases of invasive ipsilateral breast tumor recurrence 
(IBTR) with 14 controls according to age, primary tumor (T) size, grading, 
presence of comedotype, hormone receptor status. Recurrent patients had a 
median age of 43 years (range 28-69), and a median T size of 7 mm (range 2-15). 
Grade III and comedotype occurred in 3 and 2 cases, respectively, all had a 
positive hormone receptor status. Unfortunately, tumor tissue from 2 of these 
recurrent cases and 1 control were not received from the pathological anatomy 
service, which was to be expected as this was a study carried out on the leftover 
of the diagnostic material and not collected ad hoc. We obtained a DIN value >2 
by the TapeStation 4200 (Agilent) in 12 of 18 evaluable cases, for an overall 
adequate DNA rate of 67%. This result is little in line with laboratory experience 
with nucleic acid studies performed on paraffin-embedded tumor tissue samples 
typically yielding optimal DIN values in about 20% more cases examined. We next 
proceeded to NGS of primary tumors. Low coverage hampered the analysis of one 
additional control. No formal statistical design was planned due to the explorative 
nature of the study, nevertheless we next extended our analysis to an intended 
cohort of 20 additional cases. This second cohort was enriched of cases with T 
size superior to 2 cm. Nevertheless, again 2 cases were not provided by the 
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service of pathology due to unavailable tissue. After discarding 2 cases with low 
coverage, mutational analysis was carried out on the remaining 16 samples. 
3.1.2 Primary tumor mutations 
 
Considering the DCIS primary tumor samples with adequate DNA and coverage 
for mutational analysis from both the case-control (N= 11) and the extended study 
(N=16) as a unique study cohort, 13 cases resulted wild type by the 50 HS panel, 
and by the CCP in 4 cases with still available tissue. 
Fourteen cases had at least one mutation, for an overall mutation rate of 52%, with 
2 mutations in 7 cases (Table 3), all validated by ddPCR. PIK3CA was the most 
commonly mutated gene, harboring 8 mutations in 7 cases. All were missense: 4 
in the helical (E542K mutations), 3 in the kinase (H1047R), and 1 in the C2 
(N345K) domains. One case presented co-existing E542K and H1047R mutations 
with variant allele frequencies (VAF) of 33% and 32%, respectively. One additional 
case had mutated AKT. All these data are consistent with the early involvement of 
PI3K/Akt dysregulation during BC development. The next most frequently 
mutated gene was TP53 which was altered in 3 cases. 
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Table 3. DCIS patient features, and mutation analysis of matched primary tumor and 
plasma samples 
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3.1.3 ctDNA in newly diagnosed and recurrent cases 
 
Customized ddPCR assays detected mutations in pre-surgery blood from 10/14 
(71%) patients harboring mutated DCIS, with variable levels among patients 






Figure 17. Mutation profile according to patient features 
 
 
Our series also included 3 recurrent patients with evaluable DNA from primary 
DCIS, resected IBTR, and matched plasma pairs. Patient #24 had no mutations in 
all surgical specimen. By contrast, patient #1 had mutated PIK3CA in each 
surgical specimen (i.e., primary DCIS, non-invasive IBTR, and subsequent triple- 
negative BC) (Figure 18), and patient #6 had an IBTR with DCIS and invasive 
breast cancer which harbored the same TP53 mutation of initial DCIS. The 
corresponding plasma samples revealed that primary DCIS mutations in PIK3CA 
and TP53 were present at the time of recurrence. 






Figure 18. Recurrent cases with primary tumor tissue and plasma samples mutation 
analysis at initial DCIS diagnosis and at the time of relapse 
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3.2 Targeted next generation sequencing in TNBC 
 
3.2.1 Patient cohort 





Pre-treatment and surgically resected 
tumor samples were from TNBC 
patients treated with 
anthracycline/taxane-based NAC and 
breast and axillary surgery between 
September 2010 and March 2016. 
Clinical and pathological data were 
retrieved from the prospectively 
maintained  pathology-based 
institutional registry [Baili P et al., 
2015]. Median patient age was 43 
years (range 32-75). Fifteen patients 
presented with stage II disease, three 
with stage III, and one patient with 
suspicious bone metastases at initial 
diagnosis. All cases but one were 
grade 3. After a median number of six 
(range 4–8) cycles of NAC, the pCR 
rate was 21%. With a median follow- 
up of 70 months (95%CI 50–81), 
seven (37%) patients had relapsed. 
Pre- and post-NAC tumor sequencing 
was feasible in 16 (84%), and 15 (79%) of the 19 cases, respectively. Inadequate 
DNA content (pre-NAC cases = 3), and unavailability of post-NAC tumor tissue (in 
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four cases achieving pCR) prevented mutation analysis in missing cases. For 12 
(63%) patients both pre- and post-NAC tumor specimens were analyzed. 
3.2.2 TNBC somatic mutations 
 
According to the 409 comprehensive cancer panel, somatic mutations were 
detected in all 31 sequenced tumor samples, with a median of four mutations per 
sample. The majority of detected mutations were missense, followed by truncating 
mutations and variants affecting splicing and the most frequent nucleotide 
variation was C > T/G > A (Figure 19, A). Among the 10 most frequently mutated 
genes we found TP53, altered in 87% of pre-NAC, and in 60% of post-NAC 
samples, followed by a long tail of less recurrently mutated gene (Figure 19, B). A 
decreased number of mutations was observed in patients ≤50 compared to 
those >50 years old, 4 (2-6) versus 7 (5-66), p= 0.002. This association is unlikely 
confounded by other factors since the proportion of stage, grade, and type of 
treatment was similar among different age categories in this case series. 
3.2.3 Genes and pathways associated with pCR 
Considering pre-NAC samples, we first assessed whether patients with pCR or 
residual disease (RD) had a different tumor mutational load. No significant 
difference was observed in the number of mutations between the two groups, both 
considering mutations with high/moderate impact, and overall detected somatic 
mutations. Furthermore, the frequency of mutated genes was similar in patients 
with and without pCR. Beside TP53 that was mutated in 87% of pre-NAC tumors, 
most genes were mutated in few patients and no significant association between 
altered genes and NAC response was found. When we grouped mutated genes by 
pathway no significant association with pCR was observed. Nevertheless, 50% of 
patients without pCR (N= 6) were characterized by alterations in pathways related 
to adaptive immunity, and in particular in B cell and T cell signaling, and in ERBB 
signaling (Figure 20). 
Results 53  
 
 
Figure 19. Mutational spectrum of triple negative breast cancer. (A) Bar plots show the number of 
somatic mutations by type, the relative frequency of nucleotide substitutions, and the number of mutations per 
sample by mutation type. (B) Oncoplot reporting the top-10 most recurrently mutated genes across the TNBC 
samples analyzed in this study. Samples are ordered according to response group. Genes are listed from top 
to bottom by decreasing frequency 
 
Figure 20. Signaling pathways associated with pCR in pre-treatment tumor specimens. 
Heatmap shows the 15 pathways (rows) preferentially mutated in patients with RD compared to those with 
pCR (columns). Asterisks indicate immune-related pathways. Blue squares indicate that the pathway is 
mutated in the sample. Mutated genes (red squares) included in each pathway are reported. 
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None of the four patients attaining pCR showed alterations in these pathways. 
Notably, primary tumors with stable and mutated mutational profile shared the 
same mean sTILs values, i.e., 13% (range 5-25%, and range 1-35%), respectively. 
After treatment with NAC, sTILs remained the same, i.e., 13% (range 3-30%) in 
stable cases whereas they reached an average value of 19% (range 5-50%) in 
cases with a modified mutational profile. 
3.2.4 Comparison between pre- and post-treatment samples 
 
Comparison of tumor mutational load between pre- (N = 16) and post-NAC (N = 15) 
samples showed no differences considering either high and moderate impact 
mutations, or all detected somatic mutations. Clustering of pre- and post-NAC 
tumor pairs according to VAF of somatic mutations showed that for some patients 
the mutational profiles of tumors were conserved during NAC, while for others pre- 
and post-NAC samples had different mutations (Figure 21, A). Examination of 
detected mutations showed that there was a portion of mutations private to (i.e., 
observed only in) pre- and post-NAC tumors; the median number of mutations 
private to pre- and post-NAC tumors was 2 (range 0–65) and 0.5 (range 0–3), 
respectively; there were very few shared mutations, and the median number of 
common mutations was 2 (range 0–10) (Figure 21, B). 
 
 
Figure 21. Evaluation of patients with matched pre- and post-NAC samples. (A) Hierarchical 
clustering analysis based on mutant allele frequency showing patients with similar (pink) or dissimilar (light 
blue) mutational profile between their pre and post-NAC samples. (B) Bar plots showing number of private pre-
NAC (black), post-NAC (grey), and shared mutations in patients with matched samples. 
A B 
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To further assess the characteristics of genomic alteration in unresponsive TNBC 
patients, we examined individual cases evaluating the different mutant allele 
frequency distribution between pre- and post-NAC sample. In eight out of 12 
(66%), the mutant alleles frequencies differ between pre- and post-NAC samples, 
identifying groups of residual mutations. The representative case of this behavior, 
patient #16, is characterized by loss of 15 genes in the post-NAC sample, and by 
the presence of residual mutations in cluster C2, represented by SOX11, TAF1L, 
and TCF7L1 genes (Figure 22, A). In four out of 12 (33%) patients, the frequency 
of single mutations did not change between pre and post-NAC conditions. 
Considering patient #4 as a representative case, the highest VAF was detected for 
cluster C1 involving LTK, SF3B1, TP53 genes in both pre- and post-NAC samples 
(Figure 22, B). Notably, all patients with stable clusters and mutation relapsed, as 
compared to 3/8 (37.5%) patients presenting different clusters in pre- and post- 
NAC samples. Globally, genes in post-NAC samples were involved in pathways 
associated with actionable targets in tumor treatment where, besides the canonical 
PI3K/Akt/mTOR, EGFR, and Ras signaling pathways the most represented terms 
were related to regulation of cell cycle processes (Table 5). 
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Figure 22. Mutant allele distribution before and after NAC. Non-synonymous mutations of 
representative patients with residual mutations in post-NAC samples (A) and without evidence of change from 
post-NAC samples (B) are grouped and represented in red-blue scale according to their frequency. 
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Table 5. Pathway enrichment analysis of mutations in cases with changed mutational 
profile before and after neoadjuvant treatment. 
Results 58  
3.3 Liquid biopsy to monitor TNBC progression 
 
Based on our experience with DCIS, and the NGS analysis of pre- and post- 
neoadjuvant samples, we next conducted an observational prospective study to 
explore the value of ctDNA as a longitudinal test for early detection of relapse in 
TNBC patients, to challenge high-depth plasma sequencing and single cell CTC 
analysis from blood drawn as means to identify druggable molecular features in 
relapsed cases. 
3.3.1 Study CONSORT 
 
Starting from 42 patients, 7 and 4 patients were excluded due to the lack of serial 
blood sampling and primary tumor tissue, respectively (Figure 23). 
Figure 23. Liquid biopsy to monitor TNBC progression: study consort. The diagram show patients 
included in each analysis and reasons for their exclusion. Green shadow: patients with primary tumor bearing 
at least one mutation; Red shadow: patients with overall ctDNA assessment :and according to different 
treatment time points and follow-up. 
Results 59  
The clinico-pathological features of the 31 patients undergoing primary tumor NGS 
and with at least two serial blood sampling representing the study cohort are listed 
in Table 6. 
 
Table 6. Prospective neoadjuvant study population 
 
All except two patients received 
anthracycline and taxane- 
based chemotherapy before 
surgery. All patients presented 
with primary tumors≥ 2 cm, and 
20/31 (64.5%) with initial nodal 
involvement. The majority of 
patients were responsive to 
NAC except 4 that anticipated 
surgery due to progressive 
disease. Four patients attained 
the pCR. At the reporting 
census date (February 12, 
2020), 12 of the 31 patients 
experienced an unfavorable 
event, including 1 contralateral 
BC, 1 loco-regional relapse, 9 
metastatic dissemination, and 1 
death for causes not related to 
BC and/or treatment. Overall a 
total of 45 specimens were 
processed, ie diagnostic biopsy 
(N= 5), surgical samples 
(N=12), and paired diagnostic 
AGE N (%) 
<50 years 19 (61.3) 
≥50 years 12 (38.7) 
CLINICAL TUMOR SIZE 
2-5 cm 22 (71.0) 
>5 cm 9 (29.0) 
CLINICAL NODAL STATUS 
N0 11 (35.5) 
N≥ 1 20 (64.5) 
CLINICAL STAGE 
II 24 (77.4) 
III 7 (22.6) 
TUMOR GRADE 
G2 1 (3.2) 
G3 26 (83.9) 
Missing 4 (12.9) 
Ki67 
<50% 6 (19.3) 
≥50% 22 (71.0) 
Missing 3 (9.7) 
TYPE OF NAC 
Anthracycline/taxane 25 (80.6) 
Anthracycline/taxane plus platins 4 (12.9) 
Other 2 (6.5) 
PATH FINDINGS 
ypT0N0 (pCR) 4 (12.9) 
ypT1N0 13 (41.9) 
ypT1Nx 2 (6.5) 
ypT2-3N0 5 (16.1) 
ypT1-3N1-3 7 (22.6) 
BREAST CANCER EVENTS (N= 12) 
Distant metastases 9 (75.0) 
Second primary 1 (8.3) 
Loco-regional relapse 1 (8.3) 
Death from any cause 1 (8.3) 
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biopsy/surgical samples (N=14). At least 1 somatic mutation was found in 22/33 
(66.6%) and in 15/21 (71.4%) samples by the 50-gene HS and CCP, respectively. 
Of note, CCP identified at least one mutation in 3/9 samples missed by the 50- 
gene HS, and in additional 12 samples processed upfront. No results were 
available in 6 samples with either panel. In total, 37 out of 45 (82.2%) cases were 
found with at least one mutation (range 1-9), and in particular in 19/37 (51%) 
multiple mutations were detected. The most frequently mutated gene was TP53 
(20/26, 76.9%), followed by PI3KCA (4/26, 15.3%), and FGFR3 (2/26, 7.7%). 
3.3.2 ctDNA in TNBC patients undergoing neoadjuvant chemotherapy 
 
Among the 26 patients evaluated for ctDNA, blood drawings were available prior, 
during, after completion of NAC, and after surgery in 13, 11, 23, and 24 patients, 
respectively. Plasma DNA was extracted from 168 samples (median per patient, 6 
samples; range 2-13 samples). The detection rate of ctDNA prior to commencing 
NAC was 10 out of 13 evaluable cases (77%) with a median VAF value of 1.36% 
and 17.55 copies/ml. At mid-course evaluation, half of these cases turned negative, 
2 presented persistent though reduced levels of ctDNA (patients #17, and #4, with 
corresponding VAF values of 0.3% and 0.24%), and 3 were missed. Following 
NAC, ctDNA was still detectable in 10 out of 23 (11 with initial assessment prior to 
commencing NAC, and 12 with initial assessment at the end of NAC) evaluable 
cases (43%) with a median VAF value of 0.3%, and 28.29 copies/ml. Overall, 
these findings suggest that NAC reduced the levels of ctDNA soon after treatment 
start, and up to undetectable levels in most of the cases at the time of surgery 
(Figure 24). 





Figure 24. Midcourse and post-NAC ctDNA changes in non responsive cases. Three 
cases (#7, 21, 26) with pre-NAC undetectable ctDNA showed the same results also at 
midcourse and post-NAC. 
 
 
3.2.3 ctDNA status, clinico-pathological features and prognosis 
 
No clinico-pathological characteristics, including systemic inflammatory indices, 
were different between patients with detectable or undetectable ctDNA either at 
baseline or at the end of NAC, though ctDNA detection after NAC appeared more 




Figure 25. Boxplot showing the distribution of the post-NAC systemic inflammmatory indices (NLR, 
LMR, platelets), and Ki-67 according to ctDNA status 
 
 
The summary of results obtained by the simultaneous consideration of all the 
variables (ctDNA, systemic inflammatory indices, Ki67 and patient age) and 
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presence/absence of unfavorable events during follow-up is detailed in the 
heatmap of Figure 26. 
 
Figure 26. Patient age, post-NAC ctDNA, Ki67 and systemic inflammatory indices as a 
function of presence/absence of relapse. The numerical variables were rescaled to the 0-1 
range 
The conversion of ctDNA status from positive at baseline to negative during and 
after completing NAC was not associated with primary tumor response, as all 13 
evaluable patients with post-NAC undetectable ctDNA levels had residual disease 
in surgical specimen. Nonetheless, all 3 evaluable patients (#3, #8, #10) who 
progressed during NAC had still detectable levels of ctDNA prior to surgery. 
A total of 11 BC events occurred among the 26 patients with detectable ctDNA 
either pre- or post-NAC. ctDNA detection partially overlapped with higher Ki67 and 
LMR values and younger age, even though ctDNA seems to better explain the 
distribution of BC events in the study population. Specifically, negative ctDNA 
occurred in 5 out of 6 patients without recurrence despite high values of Ki67, 
whereas positive ctDNA occurred in 1 out of 3 relapsed patients despite low levels 
of Ki67. 




Figure 27. Kaplan-Meier event-free survival. The curves 
represents event-free survival according to post-NAC ctDNA 
status. Number of patients at risk and censored are shown at 
the figure bottom. 
Survival curves showed no 
difference in clinical 
outcome between patients 
with detectable ctDNA at 
baseline (pre-NAC, N= 10) 
and those with no 
detectable ctDNA (N= 3), 
with 2-year EFS estimates 
of 57.1% (95% Confidence 
Interval   [CI]:   32.6-100%) 
 
versus 66.7% (95% CI: 
 
30.0-100%), respectively. 
More   strikingly,   patients 
with post-NAC ctDNA-positive status (N= 10) as compared to those with 
undetectable ctDNA (N= 13) had an increased risk of recurrence after surgery, 
with 2-year EFS estimates of 40.0% (95% CI: 18.7-85.5%) versus 83.9% (95% CI: 
65.7-100%) (Figure 27, univariable Cox model HR 2.65; 95% CI: 0.74-9.44). 
Notably, the prognostic value of post-NAC ctDNA remained worth of consideration 
even after adjustment for age, Ki67, residual disease at surgery, and systemic 
inflammmatory indices (HR 1.91; 95% CI: 0.51-7.08) . 
3.3.4 Serial ctDNA and patient outcome 
All the patients with detectable levels of ctDNA at either pre-or post-NAC sampling 
were longitudinally monitored after surgery with the exception of two (#13 and #16) 
which had detectable ctDNA prior to surgery, recurred 7.2 and 9.3 months after 
surgery, and were not tested during follow-up. The dynamics of ctDNA during 
follow-up and the lead-time of molecular compared to clinical progression is 
detailed for individual patients in Figure 28. The first post-operative sample 
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showed undetectable levels of ctDNA in 20 of 24 (83.3%) evaluable cases. Among 
the patients with persistent levels of ctDNA, three (#14, #17 and #18) experienced 
a BC event after an average of 6.5 months from surgery, while patient #5, that 
showed a transient peak of ctDNA followed by consistently negative levels, is still 
disease-free up to 4 years from surgery. Three patients (#1, #11, and #12) turned 
ctDNA positive during follow-up after an average of 12.7 months from surgery, and 
in these patients ctDNA anticipated overt metastases by a mean of 8.9 months 
(range 6.5-13.1). Thus, the positive predictive value of detectable levels of ctDNA 








Among the 17 patients with persistently undetectable ctDNA after NAC, 14 
remained disease-free at a median follow-up of 3 years (range, 0.5-6.5). Two 
patients (# 24 and #26) tested negative prior and after NAC, and one additional 
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patient (#10) with detectable post-NAC ctDNA, were diagnosed with bone 
metastases, loco-regional relapse, and contralateral BC in absence of detectable 
ctDNA. Thus, the negative predictive value of undetectable levels of ctDNA after 
surgery was demonstrated in 14/17 cases (82.3%). 
3.3.5 Direct plasma sequencing in recurrent patients 
 
Eight recurrent patients had plasma samples collected following NAC (#13), after 
surgery (#17), or at the time of clinical relapse (#1, 11, 12, 14, 18 and 24), allowing 
a further analysis using the NGS panel of 52 cancer-related genes. No mutations 
were found in 3 cases. Notably, 2 of these cases (#13 and 17) had instead 
detectable ctDNA by ddPCR, though with low VAF values of 0.04% and 0.14%, 
respectively. In the remaining 5 cases, a median of 2 mutations per sample was 
found, with median higher VAF values of 10.35% (0.7-80%) (Table 7). All patients 
retained at least one of the primary tumor mutations. However, patients #12 and 
#14 lost mutated ATM and TP53 found in surgical samples, patient #11 gained an 
extra mutation in TP53 (VAF 80%), and patient #18 a de novo mutation in 
MAP2K2 (VAF 0.75%). Taken together, these data imply that ctDNA, while 
retaining the dominant features of the primary tumor, is informative of genetic 
alterations occurring during progression. 
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3.3.6 Analysis of CTCs in recurrent cases 
To further characterize liquid biopsies at time of disease progression, CTCs were 
detected and molecularly profiled in 6 relapsed patients. Among the 21 CTCs 
collected, 1 expressed epithelial markers (eCTCs) only, corresponding to the 
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classical CTC definition, and 20 CTCs lacked both epithelial and leukocyte 
markers or expressed more than one marker. Those latter CTCs that did not meet 
the classical CTC definition were characterized by aberrant genomes and were 
considered as non-conventional CTC (ncCTCs). The molecular characterization of 
recovered CTCs showed a prevalence of deletions on amplifications, and included 
chromosomes 5, 8, 17 (Figure 29, panel A), which have already been described in 
the literature as frequently loss in primary TNBCs [Li Z et al., 2020]. Moreover, the 
10q and 21q were the most frequently altered chromosomal arms (Figure 29, 
panel B). A network analysis of physical interaction among BC-related genes from 
these altered regions identified a module of 28 nodes involved in therapeutically 
exploitable pathways including mismatch repair, PI3K/Akt, erbB, Raf, platinum- 










Figure 29. Copy number alterations (CNAs) detected in CTCs from relapsed cases. 
A) The barplot shows the distribution of CNAs along chromosomes considering all the CTCs collected at time 
of relapse. Red and blue colors refer to amplifications and deletions, respectively. B) The heatmap reports 
patients on the column and the top 20 altered chromosomes arms on the rows. Red and blue colors refer to 
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This study provides an overview of the genomic alterations in matched pre- 
invasive and invasive primary breast cancer, and pre- and post-treatment triple 
negative breast cancer specimens. The characterization of molecular alterations 
represented in ductal carcinoma in situ, and unresponsive primary triple negative 
breast cancer cases, and their tracking in bloodstream might offer promising new 
strategies in the management of patients to prevent, and overcome tumor 
progression. 
Starting with ductal carcinoma in situ, our results extended the value of ctDNA to 
pre-invasive forms and represent, to our knowledge, the first report showing that 
primary DCIS mutations can be found in plasma samples in a similar manner to 
invasive counterparts, possibly with lower VAF values. Despite the wealth of 
published data, evidence from the literature showed the absence of significant 
genetic differences between DCIS, and invasive cancer [Sheek K et al., 2019], and 
studies suggesting otherwise were limited by the small sample size analyzed, or 
lack of functional applicability [Pang JB et al., 2017; Abba MC et al., 2015 ]. With 
this in mind, we planned to analyze the DCIS population from current clinical 
practice, with a 6-year follow-up, and a number of secondary events consistent 
with literature data [EBCTCG, 2010]. Unfortunately, our initial intention to evaluate 
ctDNA in women with and without relapse was prevented by the fact that half of 
the cases were not evaluable. This was to be expected since the retrospective 
nature of the study, and in fact the analysis was carried out on leftover tissue 
rather than on ad hoc collected specimens. Besides, most DCIS specimens are 
usually small, or have low overall cellularity, posing significant challenges in the 
generation of high throughput sequencing libraries [Nachmanson D et al., 2020]. 
Despite this limitation, our data showed ctDNA in 2/3 (67%) of evaluable recurrent 
cases as compared with 4/8 (50%) matched evaluable controls. By enriching the 
study population with additional 20 non recurrent cases with primary tumor size 
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greater than 2 cm we had fewer technical problems. As a consequence, we 
increased our ability to successfully profile up to 16/18 (80%) cases finding ctDNA 
in all 8 cases bearing at least one primary tumor mutation. So that ctDNA marks at 
least half of newly diagnosed DCIS cases seems to us to be safe to say. Whether 
it can mark a DCIS more prone to recurrence remains to be demonstrated within 
planned clinical trials overcoming technical challenges Martínez-Pérez C et al., 
2017], including more patients, and extending follow-up. Several biomarkers are 
being investigated to define patients who will develop invasive recurrence after 
DCIS. This would allow to reduce the prescription of adjuvant treatment to 
operated patients, or even to avoid surgery in extremely indolent cases [van Seijen 
M et al., 2019]. 
Our exploratory analysis suggests that ctDNA in operated DCIS could have the 
same application as in invasive cancer, i.e., it could be used to monitor patients 
over time. Indeed, our data tell us on the one hand that women with DCIS may 
present with basal ctDNA, and on the other hand that the same ctDNA is present 
at the time of recurrence. Unfortunately, since we do not have intermediate 
samples, we cannot know if, as in the case of recurrence from operated invasive 
disease [Di Cosimo S et al., 2019], also that from operated DCIS can be 
anticipated. Finally, the DCIS findings are warning about the use of direct 
sequencing panels on healthy populations [Cohen JD et al., 2018], since ctDNA 
may be present also in the absence of a frankly invasive tumor. 
Moving to NGS in TNBC analysis, we recognize that mutational profile of breast 
cancer has been widely explored in multiple contexts [Rossing M et al., 2019]. This 
study conducted a focused assessment of mutational changes in primary TNBC 
exposed to standard neoadjuvant chemotherapy, matched pairs in 63% of cases, 
over a limited time period, providing an opportunity to isolate anthracycline and 
taxane associated genomic changes in this clinical context. 
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Our primary results included the finding that TNBC is a very heterogeneous 
disease with few recurrent mutations. The unique exception was represented by 
TP53, which was found altered in 87% of pre-treatment samples, a finding in line 
with prior studies [Balko JM et al., 2014; Lips EH et al., 2015], including the TCGA 
dataset (http://portal.gdc.cancer.gov). In fact, we were not able to find specific 
tumor somatic mutations associated with response/resistance to neoadjuvant 
chemotherapy. 
Nevertheless, albeit the sample size, by using external knowledge, i.e., canonical 
pathways from MSigDB, we reported that none of the patients attaining pCR 
presented alterations in the immune related processes. As known, increasing data 
support the role of environmental factors in the escape of the tumor cells from the 
effect of cytotoxic agents. In particular, the influence of innate, and adaptive 
immune responses on the efficacy of chemotherapy has been intensely examined 
and recently reviewed [Binnewies M et al., 2018]. Tumor associated macrophages 
have been documented to contribute to doxorubicin and paclitaxel resistance by 
direct cathepsin protease Band S-mediated effects; in addition, their increased 
influx into tumors leads to a surge of regulatory T and B cells that is accompanied 
by impaired recruitment of cytotoxic T cells [Shree T et al., 2011]. On the other 
hand, several chemotherapeutic agents, including doxorubicin, are able to induce 
immunogenic cell death, antigen-presenting ability of dendritic cells, and a 
subsequent T cell response [Rapoport BL et al., 2019]. Our analysis revealed that 
TNBC tumors bearing proficient genes involved in the immune pathways are much 
more sensitive to chemotherapy. 
Although our findings require confirmation in larger datasets, evaluation of 
additional variables including disease, diet, and lifestyle, preferably originating 
from prospective clinical studies, they provide the impetus for using a target gene 
profile to aid an effective strategy with near-term clinical impact on TNBC 
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management, by identifying those patients who might benefit from neoadjuvant 
chemotherapy, and directing the remaining patients to novel therapeutic strategies 
including immunotherapy, based on the profile of residual disease. As known, the 
FDA has recently approved atezolizumab as an immunotherapy for TNBC 
treatment (http://fda.gov), here we provide evidence of other pathways of the 
immune system that could also serve as targets for novel TNBC therapies. Notably, 
based on our analysis of deregulated immune response in unresponsive patients, 
we point out that deregulated NF-kappa-B signaling is known to be implicated in 
the pathogenesis of numerous human inflammatory disorders, and malignancies. 
Consequently, the NF-kappa-B pathway has attracted attention as a promising 
therapeutic target for drug discovery, and different compounds have been 
characterized, with many demonstrating promising efficacy in pre-clinical models 
of cancer and inflammatory disease [reviewed by Awasthee N et al., 2019]. Finally, 
treatments that increase RNase L activity directly or indirectly are predicted to 
increase the antitumor activities of well-known anticancer compounds, including 5- 
azacytidine [Banerjee S et al., 2019]. 
We further reported that the overall number of tumor somatic mutations was not 
increased after neoadjuvant chemotherapy. When considering previous studies 
[Balko JM et al., 2014; Lips EH et al., 2015], our findings reinforce the concept that 
mutation changes may be related to the different chemosensitivity levels of mutant, 
and wild-type cancer cells. For patients who had loss of mutations after 
neoadjuvant chemotherapy, it is likely that their cancer cells with certain mutations 
might be sensitive to chemotherapeutic agents. Therefore, cytotoxic therapy would 
primarily remove the mutant cells and consequently shift the evolutionary 
landscape in favor of the non-mutant subclones. Conversely, for patients without 
loss of mutations after neoadjuvant chemotherapy, cancer cells might be resistant 
to chemotherapeutic agents and in the residual tumors, the mutant alleles remain 
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or become enriched. We further observed tumor somatic mutations private to pre- 
and post-treatment samples, and found that they are primarily sub-clonal. Hence 
the overall effect of neoadjuvant chemotherapy is the reduction of the total number 
of mutations, and the appearance of new mutations not detected in pre-treatment 
samples. While this finding may be consistent with neoadjuvant chemotherapy- 
induced subclone reduction, and selection of pre-existing clones with low rate 
mutations, the confounding effects of tumor spatial heterogeneity, as observed in 
multi-regional biopsies, cannot be completely ruled out with this analysis alone 
[Martelotto LG et al., 2014]. 
By hierarchical clustering, we found that all patients with concordant pre- and post- 
treatment clusters or mutations (such as in the case of p15 which presented a 
unique TP53 mutation before and after therapy) relapsed as compared to 37.5% of 
those with neoadjuvant chemotherapy-induced changes. Prior studies, reviewed 
by [Pribluda A et al., 2015], found that intratumoral heterogeneity (variably defined) 
was associated with survival and response to therapy. While this may reflect 
intrinsic tumor biology, our results suggest that stable post-treatment mutational 
profile (perhaps reflecting broad tolerance to treatment) may provide additional 
prognostic information; thereof, both pre- and post-treatment assessments of 
intratumoral heterogeneity may aid in risk stratification and should be explicitly 
assessed in future clinical trials. In addition, albeit the small sample size, basal 
and post treatment sTILs appear to be higher in tumors with changed mutational 
profile upon neoadjuvant chemotherapy, a result which is consistent with a 
possible anti-tumor effect of chemotherapy through modulation of the immune 
system [Dieci MV et al., 2014; Luen SJ et al., 2019]. Additional studies examining 
the tumor immunological landscape and response to chemotherapy through 
different “omics” in pre-and post-treatment settings may clarify this relation further. 
Recently, TNBC has been classified by gene expression into four different 
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subtypes by taking into consideration the contribution of transcripts from normal 
stromal and immune cells in the tumor environment [Lehmann BD et al., 2016]. 
These four TNBC subtypes differed in their response to standard neoadjuvant 
chemotherapy, with basal tumors having a better response than non-basal. 
Noteworthy, the luminal androgen receptor (LAR) subtype, which indeed presents 
increased AR signaling, had better survival despite a decreased response to 
neoadjuvant chemotherapy. 
Although few patients shared similar tumor mutational profiles, common pathways 
in unresponsive cases included those of regulation of cell cycle progress, PI3K/Akt 
and mTOR signaling, EGFR tyrosine kinase inhibitor resistance. Network analysis 
revealed connectivity among somatic variants in unresponsive cases that defined 
highly connected modules including PI3K/Akt (KEGG-hsa04151), ERBB (KEGG- 
hsa04012), Ras (KEGG-hsa04014), Notch (KEGG-hsa04330), androgen receptor 
signaling pathways (GO:0030521), and mismatch repair (KEGG-hsa03430). 
Altogether, these results provide support to the concept that, despite the lack of 
common mutations in patients not attaining pCR, the mutations fell into several, 
and druggable shared functional categories. Our study has also several limitations. 
The power of analysis was compromised because of small capacity, and number 
of events. Moreover, it suffered the lack of sufficient pre-treatment tumor tissue for 
microdissection, and mutation analysis to address the issue of intratumor spatial 
heterogeneity. Furthermore, additional studies are warranted to explore the 
mechanisms resulting in neoadjuvant chemotherapy-induced mutational changes, 
the functional evaluation of emerging mutations involved in potential resistance, as 
well as proliferation advantage, and the value of immune response to conventional 
chemotherapy. Importantly, the costs of serial sequencing assays preclude its 
clinical implication, which might be overcome with technology improvement. Given 
that targeted gene sequencing dynamics might serve as a potential marker of 
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chemo-sensitivity, its clinical value should be further validated in larger series of 
patients with TNBC. 
We next challenged the use of ctDNA as a tool to anticipate response to 
neoadjuvant chemotherapy, establish distinct prognostic groups after surgery, 
optimize follow-up by identifying recurrent patients in advance, and the use of 
CTCs to explore druggable targets at disease progression. 
Few studies have evaluated whether ctDNA analysis can be informative of 
response to neoadjuvant chemotherapy. In a prospective cohort of 101 patients 
with different breast cancer subtypes (84 treated with neoadjuvant chemotherapy), 
ctDNA was detected before any treatment in 41 cases and significantly associated 
with poor prognosis. Notably, ctDNA was found to anticipate the diagnosis of overt 
metastases in 16 cases [Garcia-Murillas I et al., 2015]. An ancillary ctDNA analysis 
of the NeoALTTO trial showed that baseline detection of PIK3CA, or TP53 
mutations in plasma samples of 28 patients was associated with poor response to 
anti-HER2 targeted therapy [Rothé F et al., 2019]. More recently, ctDNA, singly 
and in association with CTCs, proved to be associated with disease outcome on 
more than 100 cases in a pre-planned correlative study from a phase 2 
randomized clinical trial on TNBC patients treated with neoadjuvant chemotherapy 
[Radovich M et al., 2020]. In terms of monitoring treatment response, reduced 
levels of multiple plasma mutations in 22 patients have been recently correlated 
with increased chances of attaining pCR [McDonald BR et al., 2019]. 
In this study, by implementing a pragmatic approach with primary tumor targeted- 
gene sequencing and patient-specific point mutations ddPCR detection, we 
analyzed a homogeneous cohort of 31 TNBC patients to first assess the clinical 
value of ctDNA at baseline, during and after treatment with curative intent. Our 
basal ctDNA detection rate of 77% was comparable with the published literature 
[Riva F et al., 2017; McDonald BR et al., 2019; Li S et al., 2020; Garcia-Murillas I 
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et al., 2020], post-treatment detection rate of 43.4% was, however, higher and 
likely reflects the fact that we had several patients with large primary tumor size, 
and positive nodal status at initial presentation, which also justifies the low rate 
(13%) of pCR reported. 
A reduction of ctDNA up to undetectable levels occurred at mid-treatment and 
continued until surgery in just over half of the patients. This finding, which is 
consistent with previous studies [Riva F et al., 2017; Kim JY et al., 2017], is only 
apparently counter-intuitive, as ctDNA is expected to become undetectable only 
for patients achieving pCR. One plausible mechanism is that chemotherapy kills 
the dividing cells most likely to contribute to ctDNA release and, because the half- 
life of ctDNA in the blood is short, leaves behind a tumor less prone to ctDNA 
release at our midcourse sampling time [Lo YM et al., 1999]. Consistent with this 
hypothesis, the findings reported in the metastatic setting show that patients with 
stable disease on-treatment presented decreased levels of ctDNA despite the lack 
of tumor response [Forshew T et al., 2012; Dawson SJ et al., 2013]. Hence, the 
same could happen in the neoadjuvant setting with the important difference that 
patients with non metastatic BC present lower ctDNA levels, which instead of 
reducing disappeared during treatment. Besides, ctDNA levels were detectable in 
patients who progressed during treatment, suggesting a role for ctDNA analysis in 
identifying tumor progression, and assaying response to neoadjuvant 
chemotherapy, as increasing ctDNA may be an indicator not only of tumor growth 
during treatment but of increased risk of recurrence. 
Our results suggest that post-treatment ctDNA is a surrogate for the emergence of 
relapse with 6/10 patients with detectable ctDNA at the end of neoadjuvant 
chemotherapy developing a breast cancer event. Remarkably, despite the small 
sample size, detection of ctDNA after neoadjuvant chemotherapy retained its 
prognostic significance even after adjusting for other clinico-pathological variables, 
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including Ki-67, whose reduction has been associated with better prognosis in 
patients who do not obtain the pCR response [Burcombe R et al., 2006; 
Jones RL et al. 2009], as 83% of non relapsed cases despite persistently high Ki- 
 
67 levels were negative for ctDNA, and 30% of relapsed patients despite 
decreased levels of Ki-67 were ctDNA positive. Hence, our data suggest that the 
evaluation of ctDNA after neoadjuvant chemotherapy could act as a clinically 
available tool that might allow clinicians to stratify patients into those who could 
benefit from “complementary” treatment, in agreement with recently published 
results [Radovich M et al., 2020]. Specifically, TNBC patients with persistent 
ctDNA levels at the end of neoadjuvant chemotherapy could benefit from 
treatment intensification, or alternative therapeutic strategies in an attempt to 
prevent the development of metastases. 
Next, we showed that in 83% of cases ctDNA preceded clinical detection of distant 
metastases by 8.9 months (range, 6.5-13.1months), and with excellent specificity. 
Therefore, ctDNA is not to be considered another prognostic factor that "on 
average" associates with the prognosis, but is rather able to predict at the 
individual patient level whether the event will happen or not, and the “lead time” 
found, which is consistent with other reports, represents a unique window of 
opportunity for the introduction of non–cross-resistant therapies to prevent overt 
clinical relapse. 
Our ctDNA analysis was restricted to the known mutation profile of the primary 
tumor, which could be considered a limitation as clonal evolution cannot be 
studied. However, focusing on the known mutation profile in the tumor may 
minimize the risk of false positives particularly in light of recent reports identifying 
plasma somatic mutations arising from clonal hematopoiesis [Razavi P et al., 
2019]. On the other hand, the analysis with the Oncomine Pan-Cancer Cell-Free 
assay showed that primary tumors and metastases exhibit high genomic 
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concordance at the plasmatic level, though additional druggable mutations such as 
MAPK may arise. 
In addition to ctDNA detection, using the marker-independent Parsortix® approach 
for CTC-enrichment coupled with positive and negative selection with the 
DEPArray™, we showed that CTCs are non conventional (i.e., non epithelial) in 
most of recurrent cases and would not have been detected by any of the 
commercially available epithelial marker approach, including Cell Search® 
[Reduzzi C et al., 2017]. Notably, analysis for copy number alterations by NGS 
displayed a unique spectrum of genetic abnormalities, including gain/loss of 
chromosomes 10 and chromosome 21q. Although changes in gene copy number, 
large and small in scale, contributed to population diversity, our analysis revealed 
a network among genomic alterations in relapsed cases that defined highly 
connected modules including HER/PI3K/Ras/JAK signalling and immune response. 
Altogether, these results provide support to the concept that despite the lack of 
common CNAs in patients who progressed after NAC, they fell into several and 
more importantly druggable shared functional categories. 
The fact that patients were prospectively recruited for the purpose of these 
analyses, which were conducted in the same laboratory with uniform methodology, 
represents the major strengths of our study. However, there are also several 
limitations to consider, some of which inherent to the observational design of the 
study, the small sample size and number of pre-NAC samples collected, and the 
variable (i.e., non standardized) timing for post-surgical blood drawings, that could 
affect the evaluation of relapse/progression anticipation. Importantly, the costs of 
serial sequencing assays and single-CTC analyses preclude their clinical routinary 
application, which might be overcome by technology improvements. Although the 
data should be interpreted with caution, emerging findings - including our results - 
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may guide the direction of future studies since risk adapted treatment strategies 
continue to be a research priority. 
In conclusion, our findings support blood-based genomic analyses as 
complementary tools to optimize monitoring and to guide therapy in TNBC patients 
treated with NAC and add and integrate previous studies demonstrating the 
clinical validity of ctDNA. Prospective trials are ongoing and will address the 






























































Conclusions 82  
The   recent   approval   of    the    first    companion    diagnostic    assay    to 
detect PIK3CA mutations both in tissue and blood samples has bridged the role of 
liquid biopsy in breast cancer management to the fore. However, its value in early- 
stage disease is yet to be clearly defined. Although our results are preliminary and 
need confirmation in larger settings, they suggest that circulating tumor DNA and 
tumor cells may be used to i) stratify patients at different risk of relapse, ii) monitor 
response to treatment, and iii) unravel treatment resistance mechanisms, thus 
discovering new putative treatment targets to be further validated, specifically: 
 In DCIS of the breast, it is possible to detect ctDNA at the initial diagnosis in 
spite of technical problems, such as low cellularity and DNA quality. ctDNA 
does not seem to be associated with clinico-pathological features used in 
clinical practice for the definition of prognosis. Hence, this result suggests that 
ctDNA could carry an alternative, and complementary information to that of 
already known prognostic factors. Notably, patients with relapse showed in 
their blood the same mutations found at initial diagnosis, and this suggests 
that ctDNA could be extended to preinvasive form and used in the same way 
as in invasive cancer.These results are also worth of consideration in light of 
the development of ctDNA in screening of healthy people for invasive 
carcinomas .
 In triple-negative breast cancer, the implementation of targeted NGS in the 
context of neoadjuvant clinical setting revealed that although recurrent 
mutations are few, unresponsive cases are more likely to present with 
alterations in immune response. This finding is important in light of the current 
development of immunotherapy of solid tumors, including breast cancer. 
Neoadjuvant chemotherapy tends to select cases enriched with alterations in 
the druggable signalling pathways. Importantly, cases showing the same
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mutational profile before and after treatment and thus unperturbed by 
treatment showed a dismal prognosis. 
 Few studies have evaluated liquid biopsy in the context of neoadjuvant 
chemotherapy, the majority are retrospective, and analyzed patients who 
differed for disease stage, type of treatment and/or with a limited number of 
blood samples collected over time. Our prospective mono-institutional study 
enrolling 42 triple negative breast cancer patients, treated with 
anthracycline/taxane/platin-based, and sampled on average seven times prior, 
during and after treatment, provides the following: ctDNA is detected in 77% of 
cases prior to NAC; patients with ctDNA at the end of NAC are more than 
twice as likely to relapse as those with undetectable ctDNA; detection of 
ctDNA during follow-up antedates clinical overt metastases up to 13 months; 
at the time of clinical progression, molecular characterization of CTCs, and 
direct targeted sequencing of ctDNA revealed therapeutically exploitable 
genomic alterations.
This study also highlighted some limitations of the current workflow that need to be 
improved. In particular, i) mutational profiling is currently not feasible for all 
patients and needs to be improved by processing a larger volume of blood or by 
optimizing DNA analysis techniques, ii) optimal timing of blood sampling has still to 
be established, and iii) extensive use in clinical practice of direct sequencing of 
plasma DNA is currently prevented by its low sensitivity. Additional research is 
also needed to elucidate why ctDNA levels vary among cancer patients, such as 
determining whether this variability is due to tumor biology and/or other factors 
such as DNA clearance from plasma. 
Our findings support the analysis of ctDNA and CTCs for monitoring TNBC patient 
response to NAC, assisting de-/escalating post-NAC strategies, anticipating the 
diagnosis of overt metastases during follow-up, and characterizing recurrent 
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disease with the ultimate goal to foster personalized management in the breast 
cancer subtype which is still defined by its lack of targets. 
At the time of writing, a prospective study is currently underway at our Institution to 
evaluate ctDNA as a tool for early detection of disease recurrence and as a tracer 
for the introduction of additional new therapy. This and the other six currently 
ongoing prospective trials worldwide, registered at www.clinicaltrials.gov, will help 
to address clinically relevant questions, with a focus on using ctDNA to allow early 
adaptation of further treatment attempts, as well as on measuring the impact of 
ctDNA analysis on long-term outcomes. 
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The pen moved fast, chasing the thoughts with difficulty. I still keep that yellow 
paper with blue lines, the kind you find at the reception of the convention center in 
Chicago. It is the treatment scheme for women with HER2 positive breast cancer 
applied today all over the world. At the bottom is the date 02/06/2007 and the 
signature of José Baselga. 
A visionary of targeted therapy, Baselga has been instrumental in the development 
of drugs already in use to benefit millions of cancer patients such as trastuzumab, 
everolimus, lapatinib, pertuzumab, or in rapid clinical development for their great 
potential such as deruxetan. 
Overcoming the division between preclinical and clinical research, the taboo of 
collaboration with the pharmaceutical industry, and academic self-reliance, 
Baselga has promoted translational research in the cooperative groups and 
scientific societies he has chaired. 
A profound supporter of young people, he has shunned teaching ex cathedra in 
favor of training in the field: laboratory and animal encounters, medical staff in 
emergency rooms, hours and hours on the wards, interviews with the families of 
those who wouldn't make it, morning meetings with coffee in hand for 
multidisciplinary and molecular boards ante litteram. Believing in it up to the end, 
working hard, documenting, sharing, holding out, not settling and above all, hoping: 
Baselga was all of this. 
He passed away on March 21, 2021 at the age of 61. He leaves us an 
extraordinary scientific legacy. It is up to us to make the best use of it, as he would 
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